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RIASSUNTO 
Introduzione: Il glioblastoma e’ un tumore maligno del cervello, della categoria dei 
gliomi, caratterizzato da rapida crescita cellulare, elevata invasivita’, aggressivita’ e 
resistenza alla radio e chemioterapia. I soggetti colpiti da questa forma tumorale, 
che costituisce circa il 50% delle neoplasie maligne cerebrali negli adulti, hanno in 
media un’aspettativa di vita di quindici mesi. Il trattamento di base prevede 
l’asportazione della massa tumorale in combinazione alla radioterapia, 
eventualmente seguite da chemioterapia con temozolomide. Data l’estrema 
necessita’ di sviluppare nuove strategie terapeutiche per questo tumore fino ad ora 
praticamente incurabile, l’individuazione dei meccanismi molecolari che sono alla 
base della proliferazione e della sopravvivenza del glioblastoma e’ di fondamentale 
importanza. 
Growth Differentiation Factor 15 (GDF15), conosciuto anche con il nome di 
Nonsteroidal Anti-Inflammatory drug-activated Gene-1 (NAG-1) o Macrophage 
Inhibitory Cytokine-1 (MIC-1) e’ una proteina della famiglia del transforming growth 
factor-β (TGF-β). Il gene che codifica per GDF15 e’ costituito da due esoni che 
generano un precursore composto da un pro-peptide di 167 amminoacidi e da un 
dominio corrispondente al peptide maturo di 112 amminoacidi. In seguito alla 
dimerizzazione, avviene il clivaggio del precursore con il successivo rilascio del 
peptide maturo di 112 amminoacidi nella matrice extracellulare, dove agisce come 
dimero biologicamente attivo. L’espressione di GDF15 nei tessuti e’ notevolmente 
indotta in risposta a stimolazione con differenti farmaci anti-infiammatori, agenti 
citotossici, agonisti dei recettori della famiglia dei peroxisome proliferator-activated 
receptors (PPAR) e farmaci antitumorali.  
Il ruolo di GDF15 nella tumorigenesi non e’ stato ancora del tutto chiarito. Evidenze 
sperimentali dimostrano che elevati livelli di trascritto sono presenti in pazienti 
durante la progressione dello stadio tumorale da astrocitoma a glioblastoma, ma altri 
studi hanno dimostrato come l’espressione di GDF15 sia indotta in risposta a 
trattamenti chemioterapici. 
Metodi: L’espressione di GDF15 mediante saggi di Real-time PCR, Western Blot ed 
Elisa e del miR-3189-3p mediante Real-time PCR e’ stata valutata nella linea 
cellulare di glioblastoma LN-229 in seguito a stimolazione con Fenofibrato. Saggi di 
transfezione in vitro sono stati effettuati allo scopo di validare il targeting del miR-
3189-3p sulla regione 3’UTR dei due geni SF3B2 e p63RhoGEF. Analisi di Real-
time PCR, Western Blot, di proliferazione e migrazione cellulare in vitro e l’iniezione 
subcutanea ed intracranica in topi nudi di cellule di glioblastoma precedentemente 
transfettate con il miR-3189-3p, sono state eseguite al fine di studiare il ruolo 
funzionale del miR-3189-3p. 
Risultati: Risultati precedentemente ottenuti nel nostro laboratorio hanno dimostrato 
che la stimolazione della linea cellulare LN-229 con il fenofibrato, un agonista di 
PPARα, determina  un aumento di espressione di GDF15.  
Nel presente studio, dall’analisi della sequenza genica di GDF15 e’ risultata di 
particolare interesse la presenza di un microRNA, miR-3189, all’interno del suo 
unico introne, in posizione prossimale all’esone 1. Il pre-mir-3189 contiene due 
sequenze di microRNA mature all’interno dell sua struttura a forcina: miR-3189-3p e 
miR-3189-5p, rispettivamente di 21 e 25 nucleotidi. Ad oggi non ci sono studi che 
abbiano riportato la funzione biologica di tale microRNA, pertanto dato il ruolo che 
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ricoprono i microRNA nella regolazione genica, scopo principale di questo lavoro e’ 
stato innanzitutto quello di definire gli effetti dei due microRNA, miR-3189-3p e -5p, 
nella funzione biologica di GDF15 nei glioblastomi.  
 Abbiamo scoperto che l’induzione del trascritto e della proteina in seguito a 
stimolazione con fenofibrato e’ accompagnata da una elevata espressione del miR-
3189-3p e precede gli eventi di apoptosi innescati dal fenofibrato. Nelle medesime 
condizioni sperimentali non e’ stata osservata invece induzione del miR-3189-5p. 
Inoltre, mediante saggi di transfezione, abbiamo dimostrato che l’espressione 
ectopica del miR-3189-3p determina una inibizione della proliferazione e della 
migrazione cellulare mediante il silenziamento di due dei suoi mRNA bersaglio 
predetti, rispettivamente il fattore di splicing SF3B2 e il fattore di scambio del 
nucleotide guanina p63RhoGEF. 
Dall’analisi di espressione genica su campioni di glioblastoma e di tessuti normali 
abbiamo trovato che ad un aumento dei livelli di espressione di GDF15 nei 
glioblastomi corrisponde un decremento dei livelli di miR-3189-3p e, in aggiunta, 
queste differenze di espressione correlano con un incremento nei livelli di SF3B2 e 
una tendenza all’aumento in p63RhoGEF. 
Infine, esperimenti di iniezione subcutanea e intracranica di cellule di glioblastoma 
precedentemente transfettate con il miR-3189-3p, hanno mostrato una inibizione 
della crescita tumorale rispetto a cellule di controllo.  
Conclusioni: Tutte queste evidenze sperimentali supportano e validano il ruolo di 
miR-3189-3p come oncosoppressore nei glioblastomi mediante il controllo della 
crescita e della migrazione cellulare attraverso il silenziamento rispettivamente di 
SF3B2 e p63RhoGEF.  
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SUMMARY 
Background: Glioblastoma is a deadly cancer characterized by rapid cell 
proliferation, high invasiveness, and resistance to radio- and chemotherapy. Patients 
with this aggressive tumor, which accounts for nearly 50% of all adult brain tumors, 
have a median survival of approximately 15 months. The standard treatment for 
glioblastoma involves invasive surgery and radiotherapy, which is often followed by 
chemotherapy with temolozomide. As the development of novel therapeutic 
treatments for glioblastoma are desperately needed, it is essential to understand the 
molecular mechanisms supporting growth and survival of this highly malignant and 
practically incurable brain tumor.  
Growth Differentiation Factor 15, GDF15, also known as Nonsteroidal Anti-
inflammatory drug-activated Gene -1 (NAG-1) or Macrophage Inhibitory Cytokine-1 
(MIC-1), is a member of the transforming growth factor-β (TGF-β) superfamily. The 
GDF15 gene is encoded by two exons to generate a precursor protein containing a 
167 amino acid pro-peptide sequence and a 112 amino acid mature domain. Upon 
dimerization, this precursor protein is cleaved resulting in the release of the 112 
amino acid mature GDF15 peptide, which is secreted into the extracellular matrix as 
a biologically active dimer. GDF15 can be induced by anti-inflammatory drugs, 
cytotoxic agents, peroxisome proliferator-activated receptor (PPAR) agonist, and 
anticancer drugs. Increased GDF15 mRNA expression has been reported in patients 
during malignant progression to glioblastoma, and others have reported that 
expression levels of GDF15 are upregulated in glioblastoma cells in response to 
cytotoxic stimuli during chemotherapy treatment. We have previously reported 
increased expression of GDF15 in the LN-229 glioblastoma cell line following the 
treatment with fenofibrate, an agonist of PPARα. In this study, we have analyzed the 
genomic sequence of GDF15 and found it contains a microRNA, miR-3189, encoded 
within its single intron at a position proximal to exon 1. The precursor sequence 
encoded by miR-3189 contains two mature microRNA sequences within the stem-
loop: miR-3189-3p and miR-3189-5p, of 21 and 25 nucleotides in length, 
respectively. The biological function of this microRNA has never been described 
before. Because of the role of microRNAs in gene regulation, we wanted to define 
the effects of these co-expressed microRNAs, miR-3189-3p and miR-3189-5p, in the 
biological function of GDF15.  
Methods: The expression of GDF15 by Real-time PCR, Western Blots and Elisa 
assays and miR-3189-3p by Real-time PCR was evaluated in LN-229 cells 
stimulated with Fenofibrate. Transfections were performed in order to validate the 
targeting of miR-3189-3p on the 3’UTR of two of its major predicted targets SF3B2 
and p63RhoGEF. The functional role of miR-3189-3p was assessed through Real-
time PCR, Western Blot, cell-growth and migration assays, and through both the 
subcutaneous and the intracranial injection in nude mice.  
Results: We found that treatment of glioblastoma cells with fenofibrate resulted in a 
striking increase in GDF15 mRNA and protein levels, which was accompanied by 
high expression of miR-3189-3p, and preceded fenofibrate-induced apoptosis. In this 
experimental condition, miR-3189-5p was not detected. Ectopic expression of miR-
3189-3p inhibited LN-229 cell growth and migration through downregulation of the 
splicing factor SF3B2 and the guanine nucleotide exchange factor p63RhoGEF, 
respectively. In comparison to the normal brain tissue, we also found that 
glioblastoma clinical samples have increased levels of GDF15 and decreased levels 
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of miR-3189-3p, and that these changes correlated with increased expression of 
SF3B2 and a trend of increased levels for p63RhoGEF. Finally, both the 
subcutaneous and the intracranial growth of glioblastoma cells expressing miR-
3189-3p were significantly reduced when compared to control cells, thus further 
validating the role of this microRNA as a tumor suppressor. 
Conclusions: Our studies have demonstrated that miR-3189-3p has a tumor-
suppressive role by controlling the growth and the migration of glioblastoma cells by 
targeting the SF3B2 and p63RhoGEF mRNAs. 
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1. NON-CODING RNAs 
One of the most important advances in the field of contemporary 
molecular biology has been the discovery of non-coding RNAs (ncRNAs) as 
molecules with biological relevant role. NcRNAs represent only a small 
fraction of the genome of prokaryotes, which is generally characterized by 
protein-coding sequence accounting for 80-95% of it. The proportion of 
protein-coding genes declines with the simultaneous complexity of the 
organisms, with a concomitant increase of the number of non-coding 
intergenic and intronic sequences, most of which are in fact transcribed. 
Therefore, there seems to exist a progressive shift in transcriptional output 
between microorganisms and multicellular organisms from mainly protein-
coding mRNAs to mainly non-coding RNAs [1,2]. Indeed, according to the 
International Human Genome Sequencing Consortium, the number of the 
protein-coding genes encoded by the human genome corresponds to a 
range of 20.000 – 25.000 and represents only 2% of the genome [3]. 
Conversely a bigger portion of the human genome (98%), previously 
considered not functional and named as “junk DNA”, originates thousands of 
RNA transcripts classified as non-coding RNAs (ncRNAs) [4]. Three major 
classes of ncRNAs have been determined on the basis of their transcript 
size: small (~18-31 nucleotides, nt), medium (~31-200 nt) and long non-
coding RNAs (lncRNAs, from 200 nt up to several hundred kilobases, kb). 
The group of small ncRNAs contains small interfering RNAs (siRNAs), 
microRNAs (miRNAs, miRs) and Piwi interacting RNAs (piRNAs), while 
medium ncRNAs mainly include small nuclear RNAs (snRNAs) and small 
nucleolar RNAs (snoRNAs). Very little is known so far about the lncRNA 
species, which are included in this novel class of non-coding RNAs.  
NcRNAs can be further divided into housekeeping ncRNAs such as 
ribosomal RNAs, transfer RNAs, snRNAs and snoRNAs having crucial roles 
in many cellular processes and regulatory RNAs such as microRNAs, 
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siRNAs, piRNAs and lncRNAs that play an important role as epigenetic 
regulators of gene expression [5]. All of these ncRNAs contribute to the 
eukaryotic complexity and play a central role in regulating cellular activities. 
 
1.1 MicroRNAs 
The discovery of microRNAs can be dated in 1993 with the 
identification in Caenorhabditis elegans of the lin-4 microRNA gene by Victor 
Ambros and colleagues [6,7]. The authors found that lin-4 functions as post-
transcriptional regulator of the timing of larval development by inhibiting the 
expression of its target mRNA lin-14 by partially base-pairing to sequences 
located in the mRNA 3’ untranslated regions (3’UTRs) [8]. Since that 
discovery microRNAs have been identified in plant and animal species [9]. In 
fact, according to the latest version of the microRNA database (miRBase, 
www.miRbase.org), issued in August 2012, 2042 and 1281 mature 
microRNAs are respectively cataloged in humans and in mice [10].  
MicroRNAs are post-transcriptional regulators of gene expression 
that function by inhibiting translation of mRNAs [11]. They are endogenously 
encoded single stranded RNAs of 18-22 nucleotides in length that inhibit 
mRNA translation through imperfect base-pairing with sequences, which are 
generally located in the 3’UTR of mRNA transcript [12]. 
 
1.1.1 MicroRNA genomic organization 
Most microRNA genes are located in the intergenic regions of the 
genome [13], implying that they are transcribed independently from other 
adjacent genes. These microRNAs can be organized as monocistronic and 
possess their own promoter, or polycistronic (clustered), with a shared 
promoter.  
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MicroRNAs are also found in the introns of annotated genes, both protein-
coding and non-coding. Similarly to the intergenic ones, also these 
microRNAs can be present as monocistronic or polycistronic and their 
expression is strictly linked to the transcription of the gene from which they 
originate.  
Some microRNAs derive from spliced-out introns that are essentially 
equivalent to the pre-microRNAs, and they are therefore called mirtrons. 
There are also few examples of exonic microRNAs. They often overlap an 
exon and an intron of a non-coding gene and their maturation often excludes 
host gene function [14] (Fig. 1).     
 
1.1.2 MicroRNA classification and nomenclature 
 Classification rules for microRNAs have not been precisely identified 
so far. MicroRNAs that possess identical sequences at nucleotides 2-8 of the 
mature form generally belong to the same “microRNA family”, for example 
the let-7 family, composed of 14 paralogs loci (microRNA sisters) [15].  
The nomenclature of microRNA genes is in part contradictory. Genes 
encoding paralogs microRNAs are indicated with lettered suffixes (for 
instance mir-125a and mir-125b). If multiple loci generate the same mature 
microRNA, numeric suffixes are added at the end of the names of the 
microRNA loci (for example, mir-125b-1 and mir-125b-2). Furthermore, each 
locus produces two microRNAs: one from the 5’ strand and one from the 3’ 
strand of the precursor, designed as -5p and -3p respectively (for example, 
miR-125a-5p and miR-125a-3p) [16]. Finally, the mature sequences are 
generally designated “miR”, whereas the precursor hairpins are labelled “mir” 
[17]. 
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Fig. 1: Genomic organization of microRNAs 
Intergenic microRNAs are found in genomic regions distinct from known transcription 
units. These microRNAs can be monocistronic (A), or polycistronic (B) where several 
microRNAs are transcribed as cluster of primary transcripts.  
Intronic microRNAs are found in the introns of annotated genes, both protein coding 
and non-coding. These microRNAs can be present as a single microRNA (C) or as a 
cluster of several microRNAs (D). Intronic microRNAs are thought to be transcribed 
from the same promoter of their host genes and processed from the introns of host 
gene trancripts. In the special case of mirtrons (E), the intron is the exact sequence 
of the pre-microRNA with splice sites on either side (denote by black asterisks). In 
this case, the Microprocessor complex is thought to be unnecessary in mirtron 
maturation. Exonic microRNAs are far rarer than either of the types mentioned 
above and often overlap an exon and an intron of a non-coding gene. These 
microRNAs are also thought to be transcribed by their host gene promoter and their 
maturation often excludes host gene function. [Adapted from Olena, 2009, Journal of 
Cellular Physiology]. 
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1.1.3 Biogenesis of canonical microRNAs 
1.1.3.1 Nuclear processing 
Except for the class of mirtrons, some viral microRNAs and 
endogenous tRNA-derived microRNAs [18], microRNA genes are 
transcribed from non-coding regions of the genome by RNA polymerase II 
(RNA pol II) into a long primary transcript (pri-microRNAs) [19]. Pri-
microRNAs contain a 5’ m7 G capping structure and 3’ poly (A) tails, typical 
properties of class II genes transcripts [19]. Pri-microRNAs can be several 
kbs long and they can contain one or more stem-loop structures [20]. Those 
microRNA precursors are subsequently trimmed at the base of the stem-loop 
by a microprocessor which consists of the nuclear Ribonuclease III, Drosha, 
and the double-stranded RNA-binding domain protein DGCR8 (DiGeorge 
syndrome critical region protein 8) into a shorter microRNA stem loop (pre-
microRNA) of approximately 60-70 nucleotides in length [21].  
 
1.1.3.2 Nuclear export 
Pre-microRNAs are recognized by a member of the karyopherin 
family of nucleocytoplasmic transport factors Exportin 5 (Exp5) which, not 
only serves as the nuclear export factor for the pre-microRNAs but also 
protects the latter from digestion by nucleases [22]. By the cooperative 
binding to its cargo and to the GTP-bound form of the cofactor Ran (Ras-
related Nuclear Protein), Ran-GTP, Exp5 transports pre-microRNAs through 
the nuclear pores into the cytoplasm [23]. Fundamental requirement for pre-
microRNA recognition by Exp5 is the presence of a >14-nt stem region along 
with a short 3’ overhang (1-8 nt) [24].  
This pre-microRNA/Exp5/Ran-GTP complex then migrates to the cytoplasm 
where hydrolysis of Ran-GTP to Ran-GDP induces release of the pre-
microRNA cargo.  
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Once in the cytoplasm, pre-microRNAs are further processed by 
another Ribonuclease III family member, Dicer, into a ~22 nt long microRNA 
duplexes, with short 3’ overhangs, consisting of a guide strand and a 
passenger strand.   
 
1.1.3.3 Strand selection 
MicroRNA duplexes associate with Argonaute proteins (Ago), the 
components of the RNA-induced silencing complex (RISC) directly bound to 
mature microRNAs [25].  
One of the two strands of the duplex remains incorporated as mature 
microRNA into the miRISC complex. At the beginning of the discovery of the 
microRNAs, it was assessed that the guide strand usually remains 
incorporated into the miRISC, while the passenger strand (named as 
microRNA*) is generally degraded [9], but increasing evidence suggests that 
also the passenger strand can be actively incorporated into the miRISC and 
works as well. Therefore the nomenclature “passenger strand” or 
“microRNA*” is not very accurate, while it seems more correct to use the 5p 
– 3p names for the two strands of the microRNA duplex, since that does not 
assume that one strand is more important than the other. Indeed, both 
strands are detected and are equally abundant in some tissues and they can 
be functional in the same way [26]. Conversely, in other tissues or under 
certain experimental conditions, there is a strong preference for one of the 
two strands via a tightly controlled mechanism that has critical biological 
implications. While the exact mechanisms involved in strand selection are 
still unclear, it has been hypothesized a role for the relative thermodynamic 
stability of the 5’ ends of the microRNA duplex. The strand with more 
unstable base pairs at its 5’ end is retained into the miRISC [27].  
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1.1.3.4 MicroRNA assembly into microribonucleoproteins 
 Following the processing, microRNAs are assembled into 
ribonucleoprotein (RNP) complexes named micro-RNPs (miRNPs) or 
microRNA-induced silencing complexes (miRISCs). 
The microRNA/RISC (miRISC) complex is composed of several 
proteins including Dicer, transactivation response RNA-binding protein 
(TRBP), protein activator of the interferon (PACT) and Argonaute (Ago) [28]. 
All these proteins were shown to participate in strand selection [29], but the 
“core” component of miRISC complex is Ago protein-family. In mammalian 
cells four different paralogs of Ago have been identified: Ago1-4. All of these 
paralogs can bind endogenous microRNAs, but only Ago2 is characterized 
by endonuclease activity to cleave complementary target mRNA sequences 
[30]. Once a microRNA is incorporated into the miRISC, the 2 – 8 
nucleotides of the microRNA composing the seed sequence are presented 
and direct Ago protein to target mRNAs. The consequent binding of 
microRNAs to the 3’ UTR region of mRNAs through an imperfect 
complementarity leads to mRNA degradation or translational inhibition [15]. 
Refer to Fig. 2 for a detailed overview of the multi-steps biogenesis of 
microRNAs.  
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Fig. 2: Schematic model of canonical and non-canonical microRNA biogenesis 
pathways.   
A - In the canonical pathways, RNA polymerase II (pol II) transcribed pri-microRNAs 
are processed in the nucleus by the Drosha–DiGeorge syndrome critical region gene 
8 (DGCR8; Pasha in Drosophila melanogaster and Caenorhabditis elegans) 
complex (also known as the Microprocessor complex) that generates ~65 nt pre-
microRNAs, a process named as “cropping”. Pre-microRNAs are then recognized 
and transported into the cytoplasm by the nuclear export factor exportin 5 (EXP5). 
!
  A - Biogenesis of canonical microRNA   B – Canonical intronic microRNA 
  C – Non-canonical intronic small RNA (mirtron) 
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The second step of microRNA processing takes place in the cytoplasm and it is 
mediate by Dicer, which catalyzes the process named as “dicing” producing 
microRNA duplexes. 
Dicer, TRBP (TAR RNA-binding protein; also known as TARBP2) or PACT (also 
known as PRKRA), and Argonaute (AGO) 1–4 (also known as EIF2C1–4) mediate 
the processing of pre-microRNA and the assembly of the RISC (RNA-induced 
silencing complex) in humans. 
B - Canonical intronic microRNAs are processed co-transcriptionally before splicing. 
They require the Microprocessor complex to be generated. The microRNA-
containing introns are spliced more slowly than the adjacent introns for unknown 
reasons. The splicing commitment complex is thought to tether the introns while 
Drosha cleaves the microRNA hairpin. The pre-microRNA enters the microRNA 
pathway, whereas the rest of the transcript undergoes pre-mRNA splicing and 
produces mature mRNA for protein synthesis.  
C - Non-canonical intronic small RNAs are produced from spliced introns and 
debranching. Because such small RNAs (called mirtrons) can derive from small 
introns whose sequences resemble pre-microRNAs, they bypass the Drosha-
processing step. Some introns have tails at either the 5′ end or 3′ end, which will be 
trimmed before pre-microRNA export. [Adapted from Kim VN, 2009, Biogenesis of 
small RNAs in animals, Nat Rev]. 
	  
	  
1.1.4 Alternative pathways of biogenesis of non-canonical microRNAs 
1.1.4.1 The Mirtron pathway 
The most noticeable Drosha-independent microRNA biogenesis 
mechanism is the mirtron pathway, first described in Drosophila 
melanogaster and in Caenorhabditis elegans [31]. Mirtrons are usually 
localized in short introns where the whole intron is equivalent to the pre-
microRNA form (Fig. 2C). Therefore the first step of mirtrons processing is 
different from the canonical pathway because the pre-microRNA is cleaved 
out from the primary transcript by the splicing machinery bypassing the 
Microprocessor activity [32]. The spliced intron is not linear, but instead it is a 
lariat in which the 3’ branchpoint site is ligated to the 5’ end of the intron. 
After the resolution of this structure by lariat debranching enzyme (LDBR), 
the intron assumes the pre-microRNA folding and it can enters the 
“canonical pathway” at this stage, being transferred into the cytoplasm by 
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Exp5, cleaved by Dicer and loaded into the RISC complex for target 
regulation [32].   
In addition to the originally described type of mirtrons, there are two 
closely related groups of mirtrons: the 3’ – and the 5’ – tailed mirtrons. Both 
of them have the intronic splicing donor and acceptor sites, but they are 
characterized by extended 3’ or 5’ single-stranded RNA tails in the pre-
microRNA form that are further trimmed by exonucleases before Dicer 
processing [33,34]. Interestingly, no 3’ tailed mirtrons have been identified so 
far in vertebrate species. Conversely, a number of 5’ tailed mirtrons have 
been found in chicken and various mammals [18,35,36]. 
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1.1.4.2 Dicer-independent processing of microRNAs 
 Dicer has been viewed as a central processing enzyme in the 
maturation of small RNAs [37], but recently functional microRNAs that are 
able to bypass Dicer activity have been discovered. For instance, processing 
of the pre-miR-451 has been shown to occur by Ago2 slicer catalytic activity 
instead of Dicer-dependent cleavage [38]. The major determinants that allow 
this alternative pathway to take place are: the presence of a short 17 bp 
stem and a 4 nt loop of miR-451 [38,39]. According to the current model, 
Ago2 binds the microRNA and cleaves the paired passenger strand 10 nt 
away from the 5’ end of the Ago2 bound microRNA guide strand [40]. 
Importantly, this discovery assigned a novel function of Ago2 protein during 
the processing step of microRNAs. Indeed, Ago2 possesses not only the 
cleavage capability of the complementary mRNA targets, but also the slicer 
activity on pre-microRNAs for the generation of functional mature 
microRNAs [40].  
 
1.1.5	   Mechanisms of microRNA-mediated post-transcriptional gene 
regulation	  
The specific sequence for mRNA targets recognition is determined by 
nucleotides 2 to 8 of the 5’ region on the guide microRNA strand. It is usually 
referred as the “seed sequence” and it is essential for the selection of target 
messenger RNAs [25]. It is well known that microRNAs recognize and bind 
complementary sequences usually located in the 3’UTR of mRNA targets, 
but recent discoveries have shown the presence of non-canonical sites both 
in the 5’UTR and in the coding sequence (CDS) of mRNAs [41]. The 
interaction between the seed sequence and the targets results in mRNA 
degradation or translational inhibition on the basis of a perfect or an 
imperfect complementarity. Indeed the presence of a perfect 
complementarity leads to mRNA strand cleavage catalyzed by Ago protein. 
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Conversely an imperfect base-pairing caused by the presence of 
mismatches and bulges excludes cleavage and promotes mRNA 
translational repression [37].   
Until today the mechanisms involved in microRNA-mediated 
repression remain elusive. A number of studies have described that 
translation-repressed mRNA and miRISC are concentrated in cytoplasmic 
foci structures termed processing bodies (P-bodies, PBs) for storage or 
mRNA decay [42]. PBs contain proteins that participate in the regulation of 
mRNA degradation pathway such as the mRNA decapping enzymes 
Dcp1/Dcp2, the 5’ – 3’ exonuclease Xrn1 [43] and the key P-/GW-body 
subunit, GW182 [44]. PBs are not the ultimate sites of microRNA-mediated 
degradation; indeed, under different stimuli such as stress signals, stored 
mRNAs can be released from PBs and they can return to polysome for 
translation [45] through a mechanism that has not yet been elucidated. 
Evidences for translational repression both at the initiation step and at the 
post-initiation step have been reported [46]. Two different mechanisms of 
microRNA-mediated repression of translation at the initiation step have been 
proposed. The first model suggests that microRNAs could interfere with 
eIF4E recruitment to the 5’ – cap structure of the mRNA, thus preventing the 
activity of this essential translation initiation factor and the subsequent 
access to mRNA by the translation apparatus [47,48]. In support of this 
model Kiriakidou and colleagues demonstrated that human Ago2 directly 
binds the mRNA cap structure by its cap-binding motif similar to that one of 
eIF4E [49]. In the second model proposed, miRISC could block the 
assembly of 80S ribosomal complex on mRNA by recruiting eIF6, a factor 
important in preventing the premature association of 60S ribosomal subunits 
with 40S subunits [50], thus determining a block in the translation initiation 
[51]. In addition to these two models, there is a number of studies that 
concluded that microRNAs could inhibit translation at the post-initiation steps 
[52,53] by inducing ribosomes to drop off prematurely from mRNAs thus 
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antagonizing translation elongation. Finally, microRNAs could promote 
mRNA degradation by inducing deadenylation of the poly-(A)tail, mediated 
by the interaction between GW182 and the poly(A)-binding protein (PABP) 
[54,55]. This event is followed by the decapping of the 5’ – terminal cap 
(m7G) and subsequent mRNA decay (Fig. 3).  
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Fig. 3: Possible mechanisms of the microRNA-mediated translation repression 
in animal cells.  
Binding of micro-ribonucleoproteins (miRNPs), possibly complexed with accessory 
factors, to mRNA 3′ UTR can induce deadenylation and decay of target mRNAs 
(upper left). Alternatively, miRNPs can repress translation initiation at either the cap-
recognition stage or the 60S subunit joining stage (bottom left). mRNAs repressed 
by deadenylation or at the translation-initiation stage are moved to P-bodies for 
either degradation or storage. The repression can also occur at post-initiation 
phases of translation, resulting in either slowed elongation or ribosome ‘drop-off’ 
(bottom right). Proteolytic cleavage of nascent polypeptides was also proposed as a 
mechanism of the microRNA-induced repression of protein production (upper-right). 
A protease (X) that might be involved in the process has not been identified. The 7-
methylguanosine cap is represented by a red circle. eIF4E, eukaryotic initiation 
factor 4E. [Adapted from Filipowicz, 2008, Nature Reviews]. 
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1.1.6 MicroRNA Target Prediction 
As previously mentioned, microRNAs can repress translation by 
binding sequences located in the 3’UTR of mRNAs and several 
computational algorithms have been developed in order to help the 
prediction of the targets. These algorithms take into consideration different 
parameters such as the seed sequence of the microRNA, the number of 
putative microRNA sites in the target mRNA, the thermodynamics of their 
interaction, conservation criteria and the context surrounding the mRNA 
binding sites. Some of the most frequently used computational tools 
currently available based on conservation criteria are miRanda [56], PicTar 
[57], TargetScan [58] and DIANA-microT [59]. Other algorithms like PITA 
[60] or rna22 [61] consider different parameters such as the free energy of 
the binding between the microRNA seed and the target and the secondary 
structures of the 3’UTRs.  
The computational approach still remains the only source for rapid 
identification of putative target transcripts, but it is important to note that 
large discrepancies between results from different algorithms exist. 
Therefore, it is recommended to use multiple algorithms, and to compare 
their results in search of shared predictions. Obviously, results from target 
prediction programs need extensive experimental validation to be eventually 
confirmed as true microRNA targets. 
Related to the overall predictions of microRNAs targets, it is generally 
thought that the percentage of the comprehensive complementarity between 
a microRNA and its targets is close to 60%, implying that a single microRNA 
can regulate many target mRNAs with similar recognition sites. Therefore, a 
single microRNA can control not only functionally-related targets, but several 
cellular pathways. Indeed it has been extensively shown that microRNAs can 
participate in essential processes such as cellular homeostasis, 
development, differentiation, proliferation, apoptosis and stress responses 
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[9,62,63]. Additionally, microRNAs can be key regulators in many 
pathological conditions including autoimmune and neurological disorders, 
heart and vascular diseases, viral infections and cancer [64].    
 
1.1.7 Multistep regulation of microRNA biogenesis 
As mentioned before, more than 60% of human protein-coding genes 
are regulated by microRNAs: thus, it is not surprising that both microRNA 
biogenesis and function are subjected to a tight control and the dysregulation 
of these events is often associated with human diseases. 
MicroRNA transcription, processing by Drosha and Dicer, the loading 
into the RISC complex and microRNA intrinsic regulation such as sequence 
modification, RNA editing, RNA methylation, microRNA stability are all 
processes that are strictly regulated as detailed below.  
 
1.1.7.1 MicroRNA transcription regulation 
So far only a small number of factors that bind directly to microRNA 
promoter elements have been identified. Among the RNA Pol II-associated 
transcription factors p53, V-Myc Avian Myelocytomatosis Viral Oncogene 
Homolog (MYC), Zinc Finger E-Box Binding Homeobox 1 (ZEB1) and 2 
(ZEB2), and myoblast determination protein 1 (MYOD1) have been recently 
identified and they can positively or negatively regulate microRNA 
expression [28,65].   
 
1.1.7.2 Drosha and Dicer processing regulation 
Several positive and negative processing factors that affect 
microRNA biogenesis have been identified. Crucial for determining 
microRNA abundance is the efficiency of Drosha-mediated processing. First 
of all, post-translational modifications can regulate the protein stability, 
 
 
28 
	  
nuclear localization and processing activity of the Microprocessor. For 
instance, phosphorylation of Drosha by GSK3β (glycogen syntetase kinase 
3β) is essential for nuclear localization of Drosha [66] and acetylation of 
Drosha inhibits its degradation [67]; in addition to those, other modifications 
specifically acting on DGCR8 influence the activity of the Microprocessor. In 
addition to post-translational modifications, there are several RNA-binding 
proteins that selectively interact with Drosha and certain pri-microRNAs 
regulating this step of processing. Among them, the helicases p68 (also 
known as DDX5, DEAD (Asp-Glu-Ala-Asp) Box Helicase 5) and p72, and 
receptor-activated SMAD proteins (R-SMADs) SMAD 1 – 3 and SMAD5 [16]. 
For example, R-SMADs interact with p68 and the stem of pri-microRNAs to 
stimulate Drosha-mediated processing of miR-21 and miR-199a [68]. 
Dicer cofactors, such as TRBP, and Ago proteins are subjected to 
post-translational modifications, which influence Dicer processing and RISC 
assembly. Moreover, factors that bind directly to specific consensus 
sequences in the terminal loop of pri- and pre-microRNAs have been 
discovered. Among them there are the heterogeneous nuclear 
ribonucleoprotein A1 (HNRNPA1), which facilitates Drosha binding to the pri-
microRNA, and the KH-type splicing regulatory protein (KSRP or KHSRP), 
which promotes both Dicer- and Drosha- mediated processing [16]. 
 
1.1.7.3 MicroRNA intrinsic regulation 
The events that change RNA sequence or structure can influence 
microRNAs maturation and turnover. For instance, the presence of single 
nucleotide polymorphisms (SNPs) can affect microRNA biogenesis and/or its 
specific targeting [69]; RNA tailing processes (untemplated nucleotididyl 
addition to the 3’ end of RNA) such as uridylation or adenylation modify pre-
microRNA and mature microRNA and can facilitate or inhibit microRNA 
decay [70,71]. The human let-7 family is the best characterized group of 
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microRNAs that undergo this type of regulation. In that case LIN28 proteins 
induce terminal uridylyl tranferases TUT4 and TUT7 to enhance 
oligouridylation of pre-let-7 blocking Dicer processing and recruiting 
exonucleases that recognize the U-tail determining microRNA decay [70].  
Adenosine to inosine (A-to-I) RNA editing carried out by ADAR 
enzymes (adenosine deaminases acting on RNA) on specific pri-microRNAs 
determines the destiny of mature microRNAs in several ways. A-to-I editing 
in the hairpin region can inhibit the processing of certain microRNAs at the 
levels of Drosha and Dicer level. Also, RNA editing within the seed region 
can modify mature microRNA target specificity, leading to the recognition of 
a new set of target mRNAs [72]. 
Other modifications such as RNA methylation have been reported: 
the human RNA methyltranferase BCDIN3D has been shown to O-methylate 
the 5’ monophosphate of the pre-miR-145 and pre-miR-23b, essential for 
Dicer processing thus interfering with this event [73].  
Although very little has been known so far about the factor involved 
in microRNA stability, the regulation of microRNAs turnover could be a major 
point of control of their abundance in the cell. Several microRNA-degrading 
enzymes have been identified in different organisms. In C. elegans, 
degradation of unprotected mature microRNAs is performed by the 5’–3’ 
exoribonuclease 1 and 2 (XRN-1 and 2) [74]. In humans, the enzymes 
XRN1, RRP41 (ribosomal RNA-processing protein 41), and PNPaseold35 
(polynucleotide phosphorylase) have been shown to participate in the 
turnover of microRNAs [75,76].   
Additionally, target mRNAs can modulate the stability of 
microRNAs: for instance high level of complementarity of the target with a 
specific microRNA could lead to microRNA degradation accompanied by 
tailing and trimming [77], but further studies are required to deepen 
understand the mechanism of target-mediated stability control.  
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1.1.8 MicroRNAs involvement in human cancer 
A significant number of microRNAs can regulate the expression of 
molecules associated with the cellular fate such as differentiation, 
proliferation, and apoptosis, implying a critical role for those microRNAs in 
the fine tuning of these processes and their possible involvement in the 
multistage events of the carcinogenesis [78]. Therefore more efforts have 
been done by researches in order to investigate and establish the role of 
microRNAs in cancer. Indeed microRNAs can affect molecular pathways in 
cancer development by targeting different oncogenes or tumor suppressors 
and they can also play a role in cancer-stem-cell biology, angiogenesis, in 
the epithelial-mesenchimal transition, metastasis and drug resistance [64]. 
Moreover, in malignant tissues microRNAs can be up or downregulated thus 
themselves can be considered as oncogenes (oncomicroRNAs) or tumor 
suppressors, respectively.  
Aberrant microRNA expression has been demonstrated essentially in every 
cancer type in which dysregulated microRNAs often target genes involved in 
cell proliferation, growth, apoptosis and migration. Hence it follows the 
importance to identify the alteration of microRNA profile in malignant cells 
compared to normal cells. Indeed tumors exhibit a specific microRNA 
signature, named as miRNome, characterizing not only the malignant state 
of the cells but also their features such as grade, stage, aggressiveness, 
vascular invasion and proliferation indexes [79].  
MicroRNA profiling is a straightforward approach to identify the possible 
contribution of microRNAs to cancer pathogenesis. It can be performed by 
using microarrays analyses and reverse transcription followed by PCR (RT-
PCR), or next generation sequencing (NGS) and it has been shown that 
microRNAs expression profile changes in most human cancers [80]. Studies 
performed using those high through-put technologies resulted in the 
identification of microRNA signature that allowed classification of cancer 
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subtypes and of different stages in tumor progression more accurately than 
standard transcriptome profiling of mRNAs [81]. The great potential of using 
microRNAs profiling is due to their stability compared to messenger RNAs 
[82] and to the modern technologies that allow their detection in virtually any 
type of tissue. Therefore microRNA expression profile can be helpful in 
diagnostic and prognostic classification of human malignancies and of 
disease progression.  
Altered expression of microRNAs in cancer can result from: 
chromosomal abnormalities such as genomic amplifications, deletions, 
mutations or single nucleotide polymorphisms (SNPs) [83,84], epigenetic 
changes [85], changes in some of the components of the microRNA 
biogenesis machinery [86] and altered transcription factors activity [87]. 
Furthermore, the presence of mutations or SNPs in the microRNA binding 
sites in the 3’UTR of oncogenes are correlated with an increased risk of 
cancer [88]. As a result of aberrant expression, microRNAs can be involved 
in the process of tumorigenesis. For example, upregulation of an oncogenic 
microRNA may lead to inhibition of a tumor-suppressor protein; conversely 
down-regulation of a tumor-suppressor microRNA can result in an increased 
expression of an oncogenic protein. The presence of a loss-of-function 
mutation in a tumor-suppressor microRNA or a mutation in a microRNA 
binding site in an oncogene mRNA can cause tumorigenesis, due to the lack 
of regulation of the protein expression. Likewise the presence of a loss-of-
function mutation in oncogenic microRNAs or mutation in tumor-suppressor 
mRNAs can reduce tumorigenesis by an increased expression of tumor-
suppressor proteins [64,89] (Fig. 4). Understanding the mechanisms 
underlying these abnormalities could allow the characterization of new 
biomarkers and the development of new molecular strategies for the therapy 
of cancer.  
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Fig. 4: Example of microRNA dysregulation in cancer. 
A – the presence of a loss-of-function mutation in a tumor-suppressor microRNA or 
a mutation in an oncogenic mRNA lead to tumorigenesis; B – the presence of a loss-
of-function mutation in an oncogenic microRNA or a mutation in a tumor-suppressor 
mRNA can reduce tumorigenesis by incresing the expression of tumor-suppressor 
proteins. [Adapted from Kong YW, 2012, Lancet Oncol].  
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2. GLIOBLASTOMA 
2.1 Glioblastoma: a brief overview 
Gliomas are primary malignant tumors developing from cells that 
support neuronal function in the central nervous system (CNS), in particular 
the precursors of astrocytes, oligodendrocytes, ependymal cells (collectively 
named as glial cells) or their progenitors/stem cells [90]. These tumors are 
named on the basis of their most common elements: astrocytoma, 
oligodendroglioma, ependymoma or a mixture of lineage termed as 
oligoastrocytoma.  
Astrocytomas account for about 85% of all gliomas and they are 
classified according to the current World Health Organization (WHO) into 
four tumor grades (I-IV), from low (grade I) to high (grade IV) on the basis of 
their histopathologic features such as nuclear atypia, mitotic activity, 
endothelial hyperplasia and necrosis [91]. Grade IV astrocytoma, also 
termed as glioblastoma multiforme (GBM) or simply glioblastoma, is the 
most malignant and the most common brain tumor [92], characterized by 
rapid proliferation, increased invasiveness and resistance to radio- and 
chemotherapy [91]. Glioblastoma can develop as a de novo neoplasm 
(primary glioblastoma) or from a lower grade astrocytoma (secondary 
glioblastoma) and the specific gene mutations that characterized these two 
subtypes are not definitive [93,94]. 
The current treatment for glioblastoma includes surgical resection, radiation 
and Temozolomide (TMZ) chemotherapy. Despite the treatment, the 
prognosis remains poor, with a median survival of less than 15 months 
[95,96] with more than half of the patients develop chemoresistance rapidly 
[97]. 
One of the major features of glioblastoma cells is their ability to infiltrate the 
surrounding normal brain, making the margins of the tumor difficult to identify 
and the surgical removal incomplete. Therefore, understanding the 
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mechanisms underlying glioma cells invasion is critical to the development of 
new therapeutic strategies that can improve the existing treatments [91].  
 
2.2 Emerging role of microRNAs as modulators in malignant 
glioblastoma 
 Increasing evidences supports a role of microRNAs as key regulators 
of the events associated with glioblastoma cell biology, thus holding a great 
potential for these molecules as future therapeutic tools. Indeed, microRNA 
expression patterns obtained by using genomic profiling techniques are 
refining glioblastoma classification and differentiation between grades and 
stages of this tumor [98].   
The most common dysregulation of microRNAs observed in 
glioblastomas seems to be overexpression, based on the systematic 
literature review published by Moller et al [98]. Among microRNAs found 
upregulated in glioblastoma, the most extensively investigated are miR-21, 
miR-10b, miR-221 and miR-222. However, other microRNAs have been 
found downregulated in glioblastoma, for instance miR-128 [108], miR-29c 
[113], miR-134 [114].   
One of the first microRNA found to be highly expressed in 
glioblastomas is miR-21, previously characterized as an oncomir in most 
cancers, as it targets tumor suppressor genes [99]. In Glioblastomas, miR-21 
was found not only to be upregulated [100], but its expression correlated with 
tumor grade and poor prognosis [101]. Another microRNA found to be over-
expressed in glioma specimens compared to non-neoplastic brain tissues is 
miR-10b [102]. This microRNA has a positive effect on proliferation, since its 
inhibition slowed down glioma cell proliferation through a mechanism that 
involved cell cycle arrest and apoptosis. Indeed, levels of miR-10b correlated 
with those of positive cell-cycle regulators as cyclins B1 and D1. Accordingly, 
it has been postulated that proliferation of glioma could be regulated by miR-
 
 
35 
	  
10b through its direct or indirect action on the cell cycle machinery [103]. 
Interstingly, the cell cycle machinery appears to be a common target for 
oncomiRs such as miR-221 and miR-222 [104]. Co-suppression of miR-
221/222 directly resulted in the up regulation of p27kip1, one of the members 
of cyclin-dependent kinase (CDK) inhibitors, which prevented cell cycle 
progression from G1 to S phase affecting the growth of glioma cells [105]. 
Conversely, over-expression of miR-221/222 resulted in a down-regulation of 
the protein tyrosine phosphatase µ (PTPµ) [106], a member of the type IIb 
subfamily of receptor PTPs (RPTP), involved in cell invasiveness and 
adhesion. While a direct effect of those miRNAs on the 3’UTR of PTPµ has 
not been investigated, down-regulation of this phosphatase has been 
determined in human glioblastoma [107]. 
As we previously mentioned, enhanced proliferation by tumor cells 
can be achieved by upregulating microRNAs or downregulating microRNAs 
that either have a positive or negative effect on cell cycle, respectively. An 
example can be provided by miR-128, a microRNA abundant in neurons, 
which is downregulated in gliomas and is associated with tumor suppressive 
effects, since its upregulation can significantly reduce glioma cell 
proliferation in vitro and glioma xenografts growth in vivo [108]. Among the 
mechanisms proposed for miR-128 are the ability to reduce glioma stem cell 
self-renewal by targeting the 3’UTR of the oncogene B lymphoma mouse 
Moloney leukemia virus insertion region (Bmi-1) [109] and the ability to 
repress the proliferation of glioma-initiating neural stem cells (giNSCs) by 
targeting the two oncogenic kinases epithelial growth factor receptor (EGFR) 
and platelet-derived growth factor receptor alpha (PDGFRα) [110]. In 
addition, miR-128 can inhibit proliferation of glioma cells by targeting E2F3a, 
a transcription factor that regulates cell cycle progression [111] and by 
targeting the tyrosine kinase Wee1, which acts as a negative regulator of 
entry to mitosis (G2 to M transition) [112].  
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Other microRNAs downregulated in glioblastomas, such as miR-29c, 
can arrest the cell-cycle at the G1 stage through repression of the cyclin-
dependent protein kinase 6 (CDK6) [113]. Others, like miR-134, can inhibit 
not only proliferation, but also invasiveness and migration and can increase 
apoptosis of glioblastoma cells by targeting Nanog transcription factor [114]. 
As the development of novel therapeutic strategies for glioblastoma 
treatment is desperately needed, it would be relevant to investigate and to 
understand the molecular mechanisms by which microRNAs can support or 
counteract growth and survival of this malignancy. 
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3. GROWTH DIFFERENTIATION FACTOR 15 (GDF15): A MODULATOR 
OF TUMORIGENESIS 
3.1 GDF15 organization, processing and signaling  
 Growth differentiation factor 15 (GDF15) is a member of the 
transforming growth factor β (TGF-β) superfamily, which comprises an 
expanding group of growth and differentiation factors with a documented role 
in proliferation, cell-differentiation, inflammation, apoptosis, angiogenesis, 
adhesion, wound healing and tissue repair [115]. GDF15 is also known as 
non-steroidal anti-inflammatory drug-activated gene 1 (NAG-1) [116], 
macrophage inhibitory cytokine I (MIC-I) [117], prostate-derived factor (PDF) 
[118], placental TGFβ (PTGFβ) [119] and placental bone morphogenetic 
protein (PLAB) [120,121]. In the brain, GDF15 is reported to be expressed in 
epithelial cells of the choroid plexus and secreted into the cerebrospinal fluid 
(CSF) [122]. 
The human GDF15 gene maps to chromosome 19 in the region p13.1-13.2 
and it is composed of two exons separated by a single intron. The gene 
generates a 308 amino acid precursor protein containing a 29 amino acid 
signal peptide, a 167 amino acid pro-peptide sequence and a 112 amino 
acid C-terminal mature domain.  
Upon the removal of the N-terminal hydrophobic signal peptide and after 
disulfide-linked dimerization, the precursor protein is cleaved at the furin-like 
RRAR proteolytic site [117] resulting in the release of the 112 amino acid 
mature GDF15 protein, which is then secreted into the extracellular matrix 
where it is a biologically active disulfide-linked homodimer [123]. The 
unprocessed precursor protein of GDF15 may additionally be secreted and it 
can bind to the extracellular matrix (Fig. 5) [124].	  	  
Similar to other members of the TGF-β  family, GDF15 signaling is 
initiated by the binding to type II TGF-β receptor that leads to the activation 
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of type I TGF-β receptor through its phosphorylation. Type I receptor then 
phosphorylates receptor-regulated SMADS that form heterodimers or trimers 
with common SMAD4 and translocate into the nucleus where they interact 
with transcriptional factors and regulate the expression of numerous genes 
[115].  
	  
	  
 
 
	  
Fig. 5: Processing and formation of mature GDF15 dimer. 
GDF15 gene maps to chromosome 19 in the region p13.1-13.2. The gene generates 
a 308 amino acid precursor protein containing a 29 amino acid signal peptide, a 167 
amino acid pro-peptide sequence and a 112 amino acid C-terminal mature domain.  
Upon the removal of the N-terminal hydrophobic signal peptide and after disulfide-
linked dimerization, the precursor protein is cleaved at the furin-like RRAR 
proteolytic site resulting in the release of the 112 amino acid mature GDF15 protein, 
which is then secreted into the extracellular matrix where it is a biologically active 
disulfide-linked homodimer. The unprocessed precursor protein of GDF15 may 
additionally be secreted and it can bind to the extracellular matrix [Adapted from 
Mimeault M, 2010, J Cell Physiol]. 
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3.2 GDF15 expression in normal tissues 
Although placenta appears to be the only tissue that expresses large 
amounts of GDF15 under basal physiologic conditions [125], the low basal 
levels present in many types of resting cells can be dramatically increased in 
response to different cellular stress signals. These signals include oxygen 
deprivation (hypoxia and anoxia) [126], short-wavelength light exposure 
[127], inflammation [119], cardiovascular diseases [128], metabolic disorders 
[129] and in different types of cancer, including those of the prostate, colon, 
pancreas and breast [130]. Interestingly, GDF15 can be strongly induced by 
anti-inflammatory drugs such as Non-steroidal Anti-Inflammatory Drugs 
(NSAIDs) as well as by several dietary compounds generally resulting in an 
anti-proliferative phenotype [131].  
 
3.3 GDF15 expression in cancer 
During the processes of cancer development and progression GDF15 
can play a dual role through both a negative and a positive modulation of cell 
proliferation, differentiation, migration, invasion, survival and apoptosis [116]. 
For instance, its expression was downregulated in colon tumors compared to 
adjacent normal tissue [132], while GDF15 serum levels were found to be 
elevated in patients with colorectal carcinoma compared to healthy controls 
[133] and elevated levels of the transcript have been found in the poorly 
differentiated cells in the sub-mucosa of the invasive areas of gastric 
cancers [134]. Moreover there are evidences of increasing serum levels of 
GDF15 in association with disease progression, shorter survival and 
recurrence [135,136]. In patients with advanced stages of cancer, serum 
levels of GDF15 can be enhanced from a mean of 0.45 ng/ml to 5 – 50 ng/ml 
or higher [137]. Noteworthy, GDF15 serum levels higher than 5 – 8 ng/ml 
cause severe anorexia/cachexia, a cancer-associated weight loss condition, 
which is common in patients with advanced tumors [129].  
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The most accepted hypothesis about the dichotomy of GDF15 in cancer 
cells is that the differential expression of this protein associates with different 
stages of tumor progression. In particular GDF15 can act as suppressor of 
tumorigenesis in normal tissue at the early stages of cancer development 
and it can promote tumor survival and invasiveness at advanced stages of 
the disease [138]. 
 
3.4 Regulation of GDF15 expression 
The human GDF15 promoter contains several cis-acting and trans-
acting elements that can be regulated by numerous transcription factors and 
mechanisms and modulated by anti-tumorigenic compounds. Previous 
studies have indeed demonstrated that the increased GDF15 expression 
after anti-cancer treatments could be mediated by the transcription factors 
Sp-1, p53, early growth response protein 1 (Egr-1) [116,139], NF-kB [140], 
poly (ADP-ribose) polymerase-1 [141] and hypoxia-inducible factor-1α (HIF-
1α) [142]. In addition, it has been observed an increase of both GDF15 
protein and mRNA by inhibiting the PI3K/AKT/GSK-3β pathway, which is 
involved in the regulation of cell-survival, proliferation and growth, thus 
suggesting that GDF15 can alter these processes [143]. Feng and 
colleagues have additionally demonstrated that Calumenin-15 (Calu-15) 
facilitates filopodia formation and consequently migration of cells by 
increasing transcription of GDF15 through the binding to its promoter region 
[144]. 
 
3.5 GDF15 in glioblastoma 
Increased GDF15 mRNA expression has been reported in gliomas of 
patients during malignant progression to glioblastoma [145], thus implying 
the identification of GDF15 as an interesting candidate biomarker. In support 
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of this hypothesis, elevated levels of GDF15 have been found in the CSF of 
patients with glioblastoma [146]. 
In addition to compounds mentioned above, numerous chemicals 
with anticancer properties are able to up-regulate GDF15 expression 
suggesting multiple mechanisms responsible for its induction [147,148,149]. 
Specifically related to glioblastomas, there are numerous experimental 
results showing an up-regulation of GDF15 expression in glioblastoma cells 
in response to cytotoxic stimuli, such as chemotherapy treatments and anti-
tumorigenic compounds with a wide range of chemical structures [148,150].  
Our laboratory has previously reported an increased expression level 
of GDF15 in the LN-229 glioblastoma cell line following the treatment with 
fenofibrate, an agonist of peroxisome proliferator activated receptor alpha 
(PPARα) [148]. 
 
 
4. FENOFIBRATE  
4.1 Molecular action of fenofibrate 
Fenofibrate belongs to the fibrates’ class of lipid-lowering drugs. It 
has been used for more than 20 years to treat endogenous hyperlipidemias, 
hypercholesterolemias and hypertriglyceridemias, both as monotherapy and 
as component of combination therapy [151]. Interestingly, fenofibrate has 
been extensively used to reduce the levels of triglycerides and cholesterol in 
plasma, to improve LDL: HDL (Low Density Lipoprotein: High Density 
Lipoprotein) ratio, and to counteract the process of atherosclerosis through 
the regulation of apolipoprotein expression [152]. Fenofibrate is rapidly 
hydrolyzed in vivo to fenofibric acid, its active metabolite, which is also 
responsible for the effects of the drug mentioned above. Fenofibrate is a 
protein-bound, lipophilic compound (2-(4((4-chlorobenzoyl)	   phenoxy)-2-
methyl-propanoic acid, 1-methylethyl ester)) activated via the hydrolysis of 
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the compound’s ester bond [153]. Generally, fibrates are considered being 
well tolerated with a low incidence of toxicity in almost every organ. 
The effects of fenofibrate to modulate genes involved in lipid 
metabolism are a consequence of its ability to activate peroxisome 
proliferator-activated receptors (PPARs). In particular, fenofibrate is a potent 
synthetic ligand for PPARα, which has been initially discovered as a 
regulator of glucose and lipid metabolism. Moreover PPARα activation 
results in anticancer properties [154].  
The activation of PPARα by fenofibrate determines an increasing 
activity of malonyl-CoA decarboxylase enzyme, that in turn inhibits malonyl-
CoA and thus decreases the inhibition of carnitine palmitoyl transferase I 
(CPT-1), responsible for transferring free fatty acyl (FFA) groups into the 
mitochondria. This event stimulates fatty acids β-Oxidation and induces a 
shift of metabolism towards the glycogenesis by increasing the concentration 
of Acetyl-CoA, which inhibits the pyruvate dehydrogenase (PDH) activity 
(Fig. 6) [153].  
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Fig. 6:  Role of fenofibrate in regulating fatty acids metabolism 
PPARα activation by fenofibrate determines an increasing activity of malonyl-CoA 
decarboxylase enzyme, that in turn inhibits malonyl-CoA and thus decreases the 
inhibition of carnitine palmitoyl transferase I (CPT-1), responsible for transferring free 
fatty acyl (FFA) groups into the mitochondria. This event stimulates fatty acids β-
Oxidation and induces a shift of metabolism towards the glycogenesis by increasing 
the concentration of Acetyl-CoA, which inhibits the pyruvate dehydrogenase (PDH) 
activity.	  
	  
 
4.2 Role of PPARα  agonist fenofibrate in anticancer treatment 
PPARα, the first PPAR to be identified [155], is a nuclear receptor 
that belongs to the steroid hormone receptor superfamily. Similarly to the 
other two isoforms PPARβ/δ and PPARγ, PPARα acts as a ligand-activated 
transcription factor. The PPARs signaling start with the binding of agonist 
ligands to PPAR receptor, which in turn triggers heterodimerization of this 
receptor with the 9-cis-retinoic acid receptor (RXR) and recruits the 
transcriptional machinery to activate PPARα-responsive genes, a process 
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known as “transactivation” [156]. The heterodimer PPAR/RXR binds specific 
responsive elements (REs) in the regulatory regions of target genes, termed 
peroxisome proliferator response elements (PPREs) which are composed of 
two direct hexanucleotide repeats spaced by one nucleotide (AGGTCA-n-
AGGTCA) [156]. The endogenous ligands that activate PPAR family 
receptors derive from fatty acids metabolism and other dietary compounds, 
hence emphasizing their important role in regulating the expression of genes 
involved in glucose and lipid metabolism [157].  
PPARα is expressed in many tissues, in particular those that require 
fatty acid oxidation as a source of energy. While the primary role of PPARα 
is to increase the cellular capacity to catabolize fatty acids [158], several 
studies suggest that activating PPARα could be useful for the prevention and 
treatment of different cancers. Indeed, PPARα ligands have both direct anti-
tumor and anti-endothelial effect in vitro [159]. In particular fenofibrate has 
been shown to possess a strong suppressive activity on the proliferation of 
melanoma, breast carcinoma and Lewis lung carcinoma cell lines [154,160]. 
Moreover fenofibrate has been shown to be able to inhibit the secretion of 
tumor-secreted growth factors such as Vascular Endothelial Growth Factor 
(VEGF) in glioblastoma [159]. 
Two potential anti-tumorigenic PPARα-dependent pathways have 
been proposed [158]. First, by inhibiting NF-kB-dependent signals such as 
the production of pro-inflammatory cytokines [161], key factors known to 
contribute to inflammation-driven carcinogenesis [162]; second, by 
negatively regulating the Warburg effect exhibited by the tumor cells, thus 
interfering with their metabolic pathway. The Warburg effect is the process 
by which despite the presence of aerobic conditions, tumour tissues 
metabolize approximately ten-fold more glucose to lactate in a given time 
than normal tissues [163]. Therefore, the activation of PPARα by its 
endogenous or exogenous ligands has two main effects: it can increase 
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mitochondrial oxidation of fatty acids thus depleting the lipid stores [164], 
and it can inhibit the expression of glutaminase, which decreases glutamine 
levels [165]. Thus, according to Otto Warburg’s discovery about the 
distinctive dependency of tumor cell metabolism from glycolysis, PPARα 
activity induced by fenofibrate should affect glycolysis/glutaminolysis by 
causing a severe energy deficit, which then results in reduced proliferation 
and induction of cell death [166].  
 
4.3 Fenofibrate-induced apoptosis in glioblastoma 
 In cell culture studies as well as in animal studies, members of fibrate 
family were shown to possess anticancer properties. Treatment of 
glioblastoma cells with ligands of PPARα (bezafibrate, gemfibrozil) 
determines growth arrest and activates apoptotic response [167]; fenofibrate 
has been shown to induce apoptosis and decrease proliferation rate in 
endometrial cancer cells [168] and in human and mouse medulloblastoma 
cells lines [152]. Despite these observations, molecular mechanism(s) of 
fenofibrate activity on cancer cells are not fully understood and it has not yet 
been elucidated what role PPARα has in the antiproliferative effect of this 
drug. Nevertheless, several studies have shown PPARα-independent 
activities of fenofibrate: for example by inhibiting Akt signalling pathway 
[154], by attenuating IGF-I mediated growth responses [152], by inhibiting 
endothelial cell growth and angiogenesis [159,169]. In addition to these 
observations, PPARα-independent effects on mitochondrial respiration [170] 
and on cell motility or gap-junction intercellular coupling have been reported 
[171].   
 There is evidence of dose-dependent and time-dependent actions of 
fenofibrate in LN-229 human glioblastoma cell-line, which is positive for 
PPARα expression. Wilk and colleagues have indeed demonstrated that 
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treating LN-229 cells with 25µM of fenofibrate resulted in G1 cell cycle arrest 
together with marginal levels of dead cells at 72 hours. Conversely, 
treatment with 50µM of fenofibrate resulted in extensive cell-death 
percentage within 72 hours. The observed delayed apoptotic effect of 
fenofibrate has been shown to be preceded by the nuclear retention and 
serine phosphorylation of the transcription factor FOXO3A, a member of the 
forkhead-box O transcription factors, resulting in the Fox-O dependent up-
regulation of the pro-apoptotic gene Bim (BCL2 Like 11). Moreover, LN-229 
treatment with siRNA against PPARα only partially rescued the cells from 
fenofibrate effects, suggesting that both PPARα-dependent and PPARα-
independent mechanisms might be responsible for the activation of the pro-
apoptotic axis FOXO3A/BIM [172]. 
 
5. THE GDF15 CO-ENCODED miR-3189 
 We have previously found that treatment of LN-229 glioblastoma cells 
with fenofibrate result in increased expression of GDF15 [148].   
 In this study, we have analyzed the genomic sequence of GDF15 and 
found that contains a microRNA, miR-3189, encoded within its single intron 
at a position proximal to exon 1. The precursor sequence encoded by miR-
3189 contains two mature microRNA sequences within the stem-loop: miR-
3189-3p and -5p, of 21 and 25 nucleotides in length, respectively (Fig. 7). 
The biological function of this microRNA has never been described before.  
Because of the role of microRNAs in gene regulation, we sought to define 
the effects of these co-expressed microRNAs, miR-3189-3p and miR-3189-
5p, in the biological function of GDF15. The following results have been 
enclosed in a manuscript submitted for publication (Duane Jeansonne*, 
Mariacristina De Luca*, Luis Marrero, Adam Lassak, Marco Pacifici, Dorota 
Wyczechowska, Anna Wilk, Krzysztof Reiss and Francesca Peruzzi. Anti-
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Tumoral Effects of miR-3189-3p in Glioblastoma. * Authors contributed 
equally). 
 
   
 
	  
Fig. 7: Schematic of the GDF15 gene: the gene encoding GDF15 is composed of a 
single intron, which contains microRNA-3189 at a position proximal to exon 1  
 
 
 
5.1 SF3B2 splicing factor and p63RhoGEF are targets of miR-3189-3p 
 According to TargetScan Prediction database (www.targetscan.org) 
the major predicted gene targets for miR-3189-3p are the splicing factor 
SF3B2 (splicing factor 3b, subunit 2, 145 kDa) and the guanine nucleotide 
exchange factor p63RhoGEF (Rho guanine nucleotide exchange factor 
(GEF) 25). These two transcripts have respectively two seeds (one 
conserved and one poorly conserved) and three seeds (one conserved and 
two poorly conserved) for miR-3189-3p in their 3’ UTR.  
 
5.1.1 The RNA spliceosomal subunit SF3B2 
 In mammals there are two different spliceosome complexes: the 
major (U2-type) and the minor (U12-type). They recognize different classes 
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of splice sites and they have a different small nuclear ribonucleoproteins 
(snRNP) composition [173]. 
 SF3B2 is one of the four splicing-associated proteins (SAPs) of the 
450 kDa SF3b complex [174], a key factor that takes part in both splicing 
pathways and it participates to the assembly of the pre-splicing complex 
[173]. SF3B2 is also named SAP145 (U2 snRNP-associated spliceosomal 
protein 145), and it has been suggested to interact with SAP49 in a U2 
snRNP-associated complex that works to tether U2 snRNP to the 
branchpoint sequence (BPS) in the introns [175]. 
Although very little has been known so far about the role of SF3B2 
(and in general about the spliceosomal subunits) in relation to cancer 
disease, it is gaining attention due to its participation in cell-cycle 
progression. Indeed there are some different studies demonstrating the 
existence of a regulatory link between the splicing factors and the events of 
the cell-cycle. Of interest, by studying the interaction between the Human 
Immunodeficiency Virus Type 1 VPR protein and host cell proteins, Terada 
and colleagues have found that Vpr colocalizes with SF3B2 in the splecked 
distribution and interferes with SF3B2 function leading to checkpoint-
mediated G2 cell cycle arrest [176]. Furthermore, it has been reported that 
by inhibiting the induction of SF3B2 there is a marked reduction in the 
percentage of T cells that entered S-phase, but they are still able to increase 
in size [177].    
 
5.1.2 The guanine nucleotide exchange factor p63RhoGEF 
 The 580 amino acids p63RhoGEF protein (63 kDa) has been 
demonstrated to belong to the DBL family of guanine nucleotide exchange 
factors (GEF) based on sequence homology criteria with the Dbl oncogene 
[178]. Rho-GEFs have the function to catalyze the conversion of the small 
RHO GTPases (as RHOA, RAC1 and CDC42) from the inactive GDP-bound 
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form to the active GTP-bound form. As the other GEFs, it is characterized by 
the presence of a DBL homology (DH) domain in tandem with a pleckstrin 
homology (PH) domain [179]. It is expressed mainly in the heart and the 
brain (particularly astrocytes and oligodendrocytes) and to activate the 
formation of stress fibers in fibroblasts and cardiomyocyte-derived H9C2 
cells specifically acting as a GEF for RHOA protein [178]. p63RhoGEF is an 
effector of the Gαq subfamily of heterotrimeric guanine nucleotide–binding 
proteins (G proteins) and thus it links G protein–coupled receptors (GPCRs) 
to the activation of RHOA and to the control of the actin cytoskeleton 
reorganization [180]. It has been clearly demonstrated that p63RhoGEF 
specifically displayed GDP/GTP exchange activity towards RHOA, but not 
towards the other two Rho GTPases RAC1 and CDC42 [178]. The full-length 
p63RhoGEF form of the protein and the N-terminally truncated form, known 
as GEFT, are encoded from the same gene and they co-exist within a single 
cell type. The splice variant GEFT misses the first 105 amino acids. 
However, both isoforms have the ability to activate RHOA, but not RAC1 and 
CDC42 and induce the formation of actin stress fibres in several cell types 
[181]. The two variants differ for their localization, due to the lack of the N-
terminal 105 amino acids in GEFT. Specifically, while p63RhoGEF localizes 
in the plasma membrane, GEFT is preferentially found in the cytoplasm 
[182]. The subcellular localization appears to determine the function of 
p63RhoGEF, which has a crucial role in serum-induced migration through 
the formation of a single polarized lamellipodial protrusion in response to 
serum stimulation. Consequently, knockdown of p63RhoGEF can suppress 
the chemotactic migration of MDA-MB-231 human breast carcinoma cells 
toward serum, but had no significant effect on the chemokinetic response 
[183].    
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Glioblastoma is one of the most aggressive brain tumors. Here, we 
found that expression levels of Growth Differentiation Factor 15, GDF15, and 
its co-encoded miRNA, miR-3189-3p, were increased by treatment of 
glioblastoma cells with fenofibrate, a lipid-lowering drug with multiple 
anticancer activities. In the same experimental setting, functionality of miR-
3189-3p was tested by RNA binding protein immunoprecipitation, and miR-
3189-3p co-immunoprecipitated with Argonaute 2 together with two of its 
major predicted gene targets, the SF3B2 splicing factor and the guanine 
nucleotide exchange factor p63RhoGEF. Overexpression of miR-3189-3p 
resulted in a significant inhibition of cell proliferation and migration through 
direct targeting of SF3B2 and p63RhoGEF, respectively. In astrocytomas 
and glioblastomas clinical samples the expression of GDF15 was 
upregulated, while levels of miR-3189-3p where decreased compared to 
controls. This attenuated expression of miR-3189-3p paralleled elevated 
expression of SF3B2, which could contribute to the activation of SF3B2 
growth promoting pathway in these tumors. Finally, miR-3189-3p-mediated 
inhibition of tumor growth in vivo further supported the function of this 
microRNA as a tumor suppressor.  
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Cell culture, transfection, and reagents 
LN-229 cells were obtained from the American Type Culture 
Collection (CRL-2611; Manassas, VA) and cultured under standard growth 
conditions. Fenofibrate was from Sigma (St. Louis, MO). MiR-3189-3p 
mirVana microRNA mimic and miR-3189-3p mirVana microRNA Inhibitor 
(anti-miR-3189-3p) were purchased from Life Technologies. For transfection 
experiments, cells were seeded at a density of 4x105 cells/60 mm dish or 
2.5x104 cells/well in a 12-well plate, and transfected using Lipofectamine 
2000 (Life Technologies, Grand Island, NY) following manufacturer’s 
instructions. For Ago2-IP experiments, cells were plated in complete medium 
(DMEM+ 10%FBS) at the concentration of 1.1x106/100 mm dish and treated 
with 50 µM of Fenofibrate for 48h. SF3B2 siRNA, p63RhoGEF siRNA, and 
Control siRNA were were purchased from Santa Cruz (Dallas, TX). PPARα  
siRNA was purchased from Thermo Scientific (Waltham, MA). PPARα 
inhibitor (GW 9962) was purchased from Enzo Life Science (Farmingdale, 
NY).   
 
Quantification of microRNAs and mRNAs Expression Levels 
Total RNA was isolated using mirVanaTM microRNA Isolation Kit 
(Ambion Life Technologies Co., Grand Island, NY) and subsequently 500 ng 
of total RNA were reverse transcribed using TaqMan® MicroRNA Reverse 
Transcription kit (Applied Biosystems Life Technologies Co., Grand Island, 
NY). The reactions were incubated for 30 min at 16 °C, 30 min at 42 °C, and 
5 min at 85 °C. microRNAs expression levels were determined using 
TaqMan® 2X Universal PCR Master Mix (Applied Biosystems Life 
Technologies Co., Grand Island, NY), following the manufacturer’s protocol. 
Each generated cDNA was amplified using the Light Cycler 480 qPCR 
system (Roche, Basel, Switzerland). The reactions were incubated for 10 
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min at 95°C, 50 cycles of 15 sec at 95°C and 1 min at 60°C. RNU6B was 
used as reference gene. 
For mRNA quantification, 500 ng of total RNA were reverse transcribed 
using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems 
Life Technologies Co., Grand Island, NY). The reactions were incubated for 
10 min at 25 °C, 120 min at 37 °C, and 5 min at 85 °C. 50 ng of cDNA were 
used to quantify by TaqMan® 2X Universal PCR Master Mix (Applied 
Biosystems Life Technologies Co., Grand Island, NY) the expression level of 
GDF15, SF3B2, p63RhoGEF and PPARα. GAPDH was utilized as reference 
gene. The reactions were incubated for 10 min at 95°C, 50 cycles of 15 sec 
at 95°C and 1 min at 60°C. The relative quantification of gene expression 
was calculated using the comparative Ct (2-ΔΔCt) method. 
 
 
RNA extraction from formalin-fixed paraffin-embedded (FFPE) tissues 
 The RNA extraction from FFPE tissues of normal control, 
astrocytoma and glioblastoma clinical samples, was performed by using the 
RNeasy FFPE kit from Qiagen (Valencia, CA) following the manufacturer’s 
procedure. For mRNA and microRNA expression quantification it was 
followed the same protocol described above. For the clinical samples relative 
quantification was represented as 1/ΔCt to maintain real differences in Ct 
values between samples.      
 
Western Blots 
LN-229 cells were collected by gently scraping in the presence of 
cold PBS, following by centrifugation and disruption of the cell pellet in lysis 
buffer (50 mM Hepes pH 7.5, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA pH 
8.4, 10% glycerol, 1% Triton-X-100) containing 1 mM of Protese Inhibitor 
Cocktail (Sigma-Aldrich, St. Louis, MO), 1 mM of PMSF (Sigma-Aldrich, St. 
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Louis, MO), 1 mM of phosphatase Inhibitor (Sigma-Aldrich, St. Louis, MO) 
and 1 mM of sodium orthovanadate. Whole-cell lysates (50 to 100 µg) were 
electrophoresed on a 4-15% SDS-PAGE gel (Mini-PROTEAN TGXTM 
Precast Gel, Biorad, Hercules, CA) and transferred to a 0.2 µm nitrocellulose 
membrane (BioRad, Hercules, CA) using the Trans-Blot TURBOTM 
apparatus (BioRad, Hercules, CA). Mouse anti-SF3B2 and rabbit anti-14-3-3 
were purchased from Santa-Cruz (Dallas, TX), mouse anti-Ago2 was 
purchased from Millipore (Billerica, MA), rabbit anti-P63RhoGEF antibody 
was obtained from GeneTex (Irvine, CA), rabbit anti-GDF15 and rabbit anti-
E2F-1 antibodies were purchased from Cell Signaling Technology (Beverly, 
MA), mouse anti-GRB2 was obtained from BD Transduction Laboratories 
(San Jose, CA).   
 
ELISA assay 
 Mature GDF15 was detected in the cell culture medium using the 
GDF15 Quantikine ELISA kit from R&D Systems (Minneapolis, MN), 
according to the manufacturer’s instructions. Sample absorbance was 
measured at 450 nm using a Bio-Rad Benchmark Plus microplate reader.  
 
RNA-binding protein Immunoprecipitation (RIP) 
RIP assay was performed using Ago2 antibody form Millipore 
(RIPAb+Ago2 RIP). This kit includes negative control mpuse IgG antibody 
and control primers specific for human FOS, which were utilized for the 
optimization of Ago2-IP in our cellular model.  
5x106 of LN-229 cells were used for Ago2-Immunoprecipitation and 5x106 
cells for the IgG isotype control; 1x106 cells were used for the extraction of 
total RNA and 1x106 cells for total protein lysates. Cells were washed twice 
with cold DPBS (Gibco Life Technologies Co., Grand Island, NY), collected 
by gently scraping with 2 ml of DPBS and centrifuged for 5 minutes, 300xg, 
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at 4°C. The cell pellet was resuspended in 500 µl of Lysis Buffer (150 mM 
KCl, 25 mM Tris-HCl pH 7.4, 5 mM EDTA, 0.5% NP40, 5 mM DTT) 
supplemented with 1 mM of Protease Inhibitor Cocktail, 1 mM of PMSF, 1 
mM of Phosphatase Inhibitor, 1 mM of sodium orthovanadate and 100 U/ml 
of RNAse Inhibitor (Applied Biosystems Life Technologies Co., Grand Island, 
NY). After 30 minutes of incubation on ice, lysates were spun at 4°C for 30 
minutes at 14.000 rpm in a microcentrifuge. 
30 µL of Pierce Protein A/G Magnetic Beads (Thermo Scientific, Waltham, 
MA) were washed three times with 1 ml of Blocking Solution (0.5% BSA 
dissolved in PBS+/+). The beads were resuspended in 250 µL of Blocking 
Solution and incubated for 1 h at 4°C with 5 µg of anti-Ago2 mouse 
monoclonal IgG1k Antibody or with isotype IgG1k control Antibody. The 
immunocomplexes were washed three times with 1 ml of Blocking Solution 
and incubation with specific lysates was carried out overnight at 4°C. Next 
day, the immunocomplexes were washed three times with 500 µL of Lysis 
Buffer supplemented with the inhibitors. Left-over IP samples before the first 
wash were collected to determine the efficiency of depletion of Ago2 from 
the cellular lysate. After the last wash, immunocomplexes were resuspended 
in 40 µL of Lysis Buffer, of which 20 µL were used for the RNA extraction 
and 20 µL for Western blot analysis.  
RNA extraction from the beads and from the left-over samples was 
performed using the mirVanaTM microRNA Isolation Kit (Ambion Life 
Technologies Co., Grand Island, NY) followed by reverse trancription and 
Real-time PCR for mRNAs and microRNAs as described above. 
The calculations of fold enrichments of the Ago2-IP samples were done 
according to a recent published work by Curtale et al [184].    
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Cloning of the p63RhoGEF and SF3B2 open reading frames 
Total RNA was isolated from LN-229 cells and reverse transcribed to 
cDNA using the High Capacity cDNA Reverse Transcription kit. The cDNA 
sequence corresponding to the open reading frame (ORF) of p63RhoGEF 
was PCR amplified. The primers used were: forward, 5’ - 
GGTGGAATTCTGCAGATATGCGGGGGGGGCACAAA and reverse, 5’-
CCACTGTGCTGGATTTACAGCTCATCTTCATCCAGCTTGG. Sequences 
compatible with pcDNA3.1(+) are underlined. Next, the pcDNA3.1(+) vector 
was digested with EcoRV. This vector and the PCR product (above) were 
digested with the Klenow fragment of DNA polymerase I to generate single-
stranded 3’-overhangs compatible between the two DNA molecules. These 
products were annealed by incubating at incremental reducing temperatures 
from 95ºC to 45ºC using a PCR cycler (Bio-Rad). The ORF sequence 
corresponding to the SF3B2 gene was also cloned into the pcDNA3.1(+) 
vector using the approach described above. The primers used were: 
forward, 5’ - GGTGGAATTCTGCAGATATGGCGACGGAGCATCCC and 
reverse, 5’ 
CCACTGTGCTGGATCTAAAACTTGAACTCCTTATATTTCTTGCTGCC.  
Sequences compatible with pcDNA3.1(+) are underlined. 
 
Cloning for microRNA Functional Analysis 
The genomic sequence corresponding to the 3’UTR of p63RhoGEF 
was PCR amplified from LN-229 cells. This PCR product was ligated into the 
multiple cloning sites downstream of the Renilla luciferase reporter gene in 
the psiCHECK-2 vector (Promega, Madison, WI). This vector also contains a 
firefly luciferase reporter sequence, which allows for normalization of 
transfection efficiency. The primers used were: forward, 5’-
CCGCTCGAGCTGGTGAAAACCATGGGGGTG, containing the XhoI 
restriction site and reverse, 5’- 
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ATAAGAATGCGGCCGCGCAGCCTCGGTGATATAACAAAACC, containing 
the NotI restriction site. The genomic sequence corresponding to the 
3’UTR of SF3B2 was also cloned into the psiCHECK-2 vector. The primers 
used were: forward, 5’-CCGCTCGAGTTCAAGTTTTAGGTCCCCTCAC, 
containing the XhoI restriction site and reverse, 5’-
ATAAGAATGCGGCCGCGGAGGCTCAGGAGTGTTAAATATTCATCTC, 
containing the NotI restriction site. The XhoI and NotI restriction sites are 
underlined.  
Mutations of the miR-3189-3p putative binding sites in the p63RhoGEF and 
SF3B2 3’UTR sequences were generated using the QuikChange Lightning 
site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA) using 
the respective psiCHECK2/3’UTR plasmids as a template.  
The oligonucleotides for the mutagenesis of p63RhoGEF sites were as 
follows: site 1 forward, 5’ – 
TCAGCCGCCTATTCCCCTTCCAGCTTCAGGGCAGTCCT, site 2 forward, 
5’ – TGGAGGAGAACACCTAGACCCTTCCACTTTTTTCTGCCCA 
AGGAAC, and site 3 forward, 5’ – 
CCCAAGGACTTTTTTCTGCCCTTCCAACACAGTTTCCTTCAGCTCC.  
The oligonucleotides for the mutagenesis of SF3B2 sites were: site 1 
forward, 5’ – 
GAACCACCTCTCCCGCAGTTCCCTTCCACTTGTCATTTCATGTTCTTAT, 
and site 2 forward, 5’ – 
GACCTGTTTTGTAAATAAAGCTGTTTCCCTTCCAAAGAGATGAATATTTA
ACACTCCTGAGC.  
Mutated bases in the miR-3189-3p binding sites were underlined. The 
reverse oligonucleotide primers were complementary to the forward primers. 
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Dual Luciferase Assay 
LN-229 cells were plated at a density of 8 x104 cells/well in a 12-well 
plate and transfected with psiCHECK-2 vector expressing target 3’UTR (160 
ng/well) alone, target 3’UTR with miR-3189-3p mimic (30 nM), or target 
3’UTR with microRNA mimic and anti-miR-3189-3p (50 nM) using 
Lipofectamine 2000. After 24 h, cells were harvested and lysates were 
assayed for luciferase activity with the Dual-Luciferase Reporter Assay 
System (Promega) using a Synergy 2 microplate reader (BioTek 
Instruments, Inc., Winooski, VT). Relative units of Renilla luciferase activity 
were normalized to the firefly luciferase internal control in each sample. 
Experiments were performed in duplicate. 
 
Generation of stable LN-229 expressing SF3B2, p63RhoGEF or miR-
3189-3p 
 In order to produce stable LN-229 expressing respectively SF3B2 
and p63RhoGEF, LN-229 cells were plated at a density of 1x106 
cells/100mm dish and transfected with pcDNA3.1(+) containing the ORF of 
SF3B2 or p63RhoGEF using the empty vector as control. After 24h the 
selecting antibiotic G418 (Gemini Bio-products, Sacramento, CA) was added 
at the concentration of 1 mg/ml and the medium was replaced every 
two/three days complete of fresh antibiotic. The cells were splitted far in 
order to permit the formation of isolated colonies. When the drug-resistant 
colonies were large enough, they were transferred into a 12-well plate by 
using the cloning cylinders and cultured with G418 at the maintenance 
concentration (0.8 mg/ml). The cells were transferred in plates progressively 
bigger and the screening of the best clone expressing the biggest amount of 
the gene of interest (GOI) was conducted by western blot analysis.  
 For the generation of stable LN-229 expressing the miR-3189-3p, the 
“Tet-On® 3G Inducible Expression Systems” from Clontech (Mountain View, 
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CA) was followed. The sequence of the mature miR-3189-3p was cloned in 
the inducible pTRE3G-IRES vector. A previously generated LN-229 clone 
with stable expression of the regulator plasmid pCMV-TET3G producing the 
Tet-On 3G protein was transfected at the density of 1.8x105 in a 6-well plate 
with the pTRE3G-IRES-miR-3189-3p vector and the linear Hygromycin B 
marker. The cells were cultured in presence of both G418 and Hygromycin B 
following the manufacturer’s protocol and the clones were grown as 
described above. The screening of the best clone was performed by 
Realtime PCR analysis of the expression level of miR-3189-3p in presence 
and in absence of Doxocyclin in the cultured cells.  
 
Cell Proliferation Assay 
LN-229 cells were plated at a density of 2.5x104 cells/well in a 12-well 
plate and transfected with mock or miR-3189-3p mimic +/- anti-miR-3189-3p. 
At 72 h after transfection, cells were incubated with medium containing 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) reagent (Promega) diluted according to manufacturer’s 
instructions. Cells were then incubated at 37°C for 30-60 min and 
absorbance was measured at a wavelength of 490 nm using a Bio-Rad 
Benchmark Plus microplate reader. 
 
Cell Cycle Analysis 
Cells were collected 48h after transfection and fixed in 70% ethanol 
overnight at -20ºC. Cells were then centrifuged at 300xg, resuspended in 
150 µL of Guava Cell Cycle reagent (Guava Technologies, Hayward, CA), 
and stained for 45 min at 25ºC while protected from light. Cells were counted 
by flow cytometry using a FACSAria (BD Biosciences). Cell cycle distribution 
was evaluated using the ModFit LT program (Verity Software House, 
Topsham, ME).  
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Scratch Assay 
LN-229 cells were transfected with miR-3189-3p and plated in a 35 
mm glass bottom dish (MatTek Corporation, Ashland, MA) at a density of 
1.8x105 cells/dish. The scratch assay was performed by moving a pipette tip 
across the cell monolayer. Migration into the cell-free area was monitored for 
up to 24h using live cell time-lapse imaging in a VivaView FL incubator 
fluorescent microscope (Olympus, Center Valley, PA).  
 
In vivo tumor growth 
Mice used for in vivo tumor growth studies were female Fox1nu 
athymic nude mice at 6-7 weeks of age (Harlan Laboratories, Inc., 
Indianapolis, IN). For the subcutaneous tumor growth, 5 mice per group 
were injected on the flank with 2x106 LN-229 glioblastoma cells stably 
expressing the mCherry fluorescent protein and mock-transfected, or 
transfected with miR-3189-3p mimic. The experiment was repeated using 
U87MG glioblastoma cells.  
For the intracranial injection of U87MG cells, 5 mice per group were 
injected with 25000 cells stably expressing the Luciferase and mock-
transfected, or transfected with miR-3189-3p mimic. All experiments were 
performed in accordance with institutional ethical guidelines. 
 
In vivo imaging tumors 
In vivo growth of LN-229-mCherry and U87MG-luciferase tumors was 
quantified by biophotonic imaging using a Xenogen IVIS 200 system 
(Xenogen, Palo Alto, CA). Prior to imaging, mice were placed in the chamber 
of an XGI-8 vaporizer and anesthesia was induced with 4% isoflurane gas. 
Anesthesia was sustained inside the imaging chamber using nose cones. 
Images were captured and quantified with Living Image 4.1 software based 
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on equivalent regions of interest over the lower back of the mouse. Image 
intensities were expressed as photon flux per second, square centimeter and 
surface radiance (photons/sec/cm2/sr).  
 
Statistical analysis 
Data are presented as mean ± SD. Comparison between two 
experimental groups was performed using the Student’s t-test. P-values ≤ 
0.05 were considered statistically significant. 
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Expression of GDF15 is increased after fenofibrate treatment 
 Previous reports have demonstrated that GDF15 expression is 
induced following treatment by a variety of chemotherapeutic agents 
[150,169]. In line with these findings, it has also reported in our laboratory 
that this gene is upregulated in a microarray analysis of glioblastoma cells 
treated with the metabolically active anticancer compound, fenofibrate [172]. 
Fenofibrate is a potent agonist of peroxisome proliferator activated receptor 
alpha (PPARα), which has exceptional anticancer properties, especially in 
tumors of neuroectodermal origin, including glioblastomas [148]. To further 
analyze the effects of fenofibrate on this gene, we have exposed the human 
glioblastoma cell line, LN-229, to 50 µM fenofibrate and monitored the 
expression of GDF15 at 24 and 48 hour time points. Following the treatment, 
total RNA was extracted and subjected to quantitative real-time PCR (qRT-
PCR) using GDF15-specific and GAPDH-specific primers. The results in Fig. 
8A, show a 60-fold upregulation of GDF15 gene expression. In agreement 
with these findings, a large increase in GDF15 protein content was detected 
by Western Blot analysis, and significant levels of secreted GDF15 were 
detected by ELISA 48 hours following fenofibrate treatment (Fig. 8B and C, 
respectively).  
 
SF3B2 and p63RhoGEF are targets of miR-3189-3p 
Since GDF15 is strongly upregulated by fenofibrate and miR-3189 is 
encoded within its intron (Fig. 7), we sought to investigate whether the 
expression of miR-3189 was contributing to the biological function of GDF15. 
We first determined whether this microRNA is expressed in glioblastoma 
cells under conditions that are known to upregulate GDF15. If so, we also 
asked whether this upregulation would be strand-specific to miR-3189-3p, -
5p, or both. To answer these questions, LN-229 cells were treated with 50 
µM fenofibrate (FF) for 48h followed by qRT-PCR analysis using RNU6B as 
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the reference gene. Fig. 9A shows the relative expression of miR-3189-3p 
and -5p in FF-treated cells as compared to untreated control. Results 
indicate that the mature microRNAs encoded by miR-3189 are differentially 
expressed with only miR-3189- 3p expression being strongly induced under 
pro-apoptosis stimuli. We next tested if miR-3189- 3p was functionally 
associated to Argonaute 2 (Ago2) complexes by RNA-IP using Ago2 
antibody followed by real time PCR (see Materials and Methods). Efficient IP 
for Ago2 was evaluated by Western blot (Fig. 9B). When compared to 
untreated cells, nearly 35-fold overexpression of miR-3189-3p linked to Ago2 
immunocomplexes was measured in extracts from fenofibrate treated cells 
(Fig. 9C). Although not necessarily related to the specific binding to miR-
3189-3p, we also measured an increase in SF3B2 and GEFT in the Ago2-IP 
complexes derived from fenofibrate-treated samples (Fig. 9D). Note that, 
although lower amounts of Ago2 were immunoprecipitated in FF-treated 
compared to untreated cells (Fig. 9B, compare lanes 6 and 8), complexes 
were still able to efficiently bind miR-3189-3p and its predicted targets 
SF3B2 and p63RhoGEF mRNAs (Fig. 9C and D). In agreement with the 
detection of SF3B2 and p63RhoGEF mRNAs in the Ago2 complex, we have 
observed a strong downregulation of SF3B2 mRNA and protein levels in 
fenofibrate treated cells compared to untreated (Fig. 10A and C). Similarly to 
SF3B2, fenofibrate induced also a downregulation of p63RhoGEF mRNA; 
however, in this case the effect was significantly less pronounced, and could 
reflect higher stability of p63RhoGEF mRNA and/or protein in fenofibrate-
treated cells (Fig. 10A and C). The direct contribution of miR-3189-3p to 
SF3B2 and p63RhoGEF mRNA and protein levels was evaluated in miR-
3189-3p transfected cells by quantitative RT-PCR and Western blot 
analyses. In comparison to controls, nearly 5-fold and 2.5-fold lower levels of 
SF3B2 mRNA and p63RhoGEF mRNA were detected in miR-3189-3p 
expressing cells, respectively (Fig. 10B). Importantly, we were able to 
counteract downregulation of these two transcripts by overexpressing the 
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anti-miR-3189-3p (miR-3189-3p inhibitor), further supporting the presence of 
miR-3189-3p-specific regulation. A remarkable down-regulation of SF3B2 
and p63RhoGEF at the translational level was confirmed by Western blots in 
cells transfected with miR-3189-3p, when compared to control or cells co-
transfected with the anti-miR- 3189-3p (Fig. 10D). There are two putative 
binding sites for miR-3189-3p in the 3’UTR sequence of SF3B2 mRNA, one 
conserved (MS2) and one non-conserved (MS1), and their expression was 
tested by a luciferase-based reporter assay (Fig. 11A). A reduction of 
approximately 75% of luminescence was observed in cells expressing miR-
3189-3p, and again this inhibition was almost completely alleviated in the 
presence of anti-miR-3189-3p. In addition, site directed mutagenesis of the 
microRNA binding sequences in the 3’UTR showed a slightly different, 
although cumulative, inhibitory activity. The conserved microRNA binding 
site (MS2) appeared to be slightly more effective in microRNA-induced 
transcript degradation as mutation of this site significantly reversed a 
decrease in luciferase signal (compare MS1 and MS2). As expected, 
mutation of both microRNA binding sequences (double mutation, DM) 
abrogated inhibition by miR-3189-3p. In fact, a slight increase in luciferase 
signal over 3’UTR alone was observed, possibly because mutation of both 
binding sequences also prevents binding by endogenous miR-3189-3p (Fig. 
11A). The p63RhoGEF 3’UTR contains three putative binding sites for miR-
3189-3p, one conserved and two non-conserved. Similarly to SF3B2 3’UTR, 
we have tested p63RhoGEF 3’UTR (Fig. 11B). Also here, the inhibition was 
efficiently reverted either in the presence of anti-miR- 3189-3p or by mutating 
the three binding sequences (triple mutation, TM) of the p63RhoGEF 3’UTR. 
Quantitatively, one of the non-conserved binding sites did not appear to be 
required for miR-3189-3p-induced gene regulation, since mutation of this site 
(MS1) failed to revert the expected inhibition. Conversely, mutation of the 
other two microRNA binding sites (MS2 and MS3), one conserved and one 
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non-conserved, showed a stronger and cumulative reversion of inhibition by 
miR-3189-3p (Fig. 11B). 
 
MiR-3189-3p regulates growth and migration of glioblastoma cells 
We next evaluated the function of miR-3189-3p in cell growth and 
migration of the human glioblastoma cell line LN-229. At 48 hours post-
transfection morphology of miR-3189-3p expressing cells was visibly altered, 
presenting a more polygonal shape when compared to the typical spindle-
shaped LN-229 cells under normal growth conditions or when both miR-
3189-3p and anti-miR-3189-3p were co-expressed (Fig. 12A). In addition, 
the expression of miR-3189-3p resulted in a 50% reduction in cell growth (% 
decrease in cell number over control; Fig. 12B), accompanied by a 
significant, 40% reduction in S phase index, as determined by cell cycle 
distribution analysis (Fig. 12C). No significant changes were observed when 
miR-3189-3p was co-transfected with anti-miR-3189-3p, and the cells 
expressing this inhibitor behaved essentially as the control, mock-transfected 
cells. Since miR-3189-3p downregulates also p63RhoGEF mRNA, we 
evaluated possible effects of this microRNA on cell migration using scratch 
assay and by monitoring both cell locomotion and cell division using time-
lapse imaging. While control cells populated the entire scratched area in 18 
hours, the cells transfected with miR-3189-3p covered only 42% of the 
scratched surface (Fig. 12D) in the same amount of time. Both decreased 
cell motility and decreased cell proliferation contributed to the observed 
attenuation of the invasion of the cell-free space. 
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Role of SF3B2 and p63RhoGEF to the inhibition of cellular growth and 
migration induced by miR-3189-3p 
Since SF3B2 expression is strongly downregulated by miR-3189-3p, 
we hypothesized that forced expression of SF3B2 might reverse the miRNA 
-mediated effects on cell proliferation. Results from growth rate analysis in 
Figure 13A provide evidence, which confirms this assumption (Fig. 13). 
Moreover, we measured that constitutive expression of SF3B2 was enough 
to rescue cell growth to steady-state levels despite addition of miR-3189-3p. 
Conversely, downregulation of SF3B2 by siRNA mimics the biological effects 
of miR-3189-3p expression by inducing 55% reduction in cell growth (Fig. 
13B). The impaired growth by SF3B2 is likely mediated by E2F-1, a known 
molecule downstream of SF3B2 that is important for cell cycle progression 
[177]. The Western blot in Fig. 13C shows marked down-regulation of E2F-1 
protein levels in LN-229 cells transfected with miR-3189-3p and this effect 
was reversed in the presence of the anti-miR-3189-3p. Therefore, these data 
suggest that E2F-1 is a potential downstream target of miR-3189-3p/SF3B2 
in coordinating delayed cell growth in our model.  
Next, we evaluated the contribution of p63RhoGEF to the inhibitory 
effects of miR-3189-3p expression on cell migration. Silencing p63RhoGEF 
in LN-229 resulted in 54% (± 7%) inhibition of migration (Fig. 14A) 
confirming previously reported data [183]. To test the contribution of 
p63RhoGEF on the inhibition of migration due to miR-3189-3p we generated 
a stable cell line over-expressing p63RhoGEF and we utilized two clones 
that showed different expression levels of the protein (Fig. 14B, inset). When 
tested using the scratch assay, both clones of the p63RhoGEF-expressing 
cells behaved essentially as the control cells (transfected with pcDNA3.1 
empty vector), however transient transfection with the miR-3189-3p was still 
capable of reducing cell migration by 60% (Fig. 14B). Altogether, those 
results indicate that downregulation of SF3B2 by miR-3189-3p is necessary 
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and sufficient for the miR-mediated impairment of cell growth, while down-
regulation of p63RhoGEF might be required but is not sufficient for the 
inhibition of migration by miR-3189-3p.  
 
MiR-3189-3p is downregulated in human brain tumors and has tumor 
suppressor activity in mice 
 Next, the ability of miR-3189-3p to inhibit tumor growth was evaluated 
in vivo. LN-229 cells, bearing the pmCherry plasmid to facilitate detection of 
the tumor by fluorescence, were mock-transfected or transfected with miR-
3189-3p mimic. Next day, 2x106 of either cell line were injected 
subcutaneously in the flank of nude mice (n=5 per group). Beginning at one 
week post-injection, mice were visualized via in vivo biophotonic 
epifluorescence and the mean fluorescence radiance for each tumor was 
collected. We found that mice bearing LN-229/miR-3189-3p cells had a 
nearly 75% smaller tumors when compared to LN-229/Mock (Fig.15, A and 
B; p<0.05). The same results were observed in nude mice bearing 
subcutaneous injection of U87MG-luciferase/miR-3189-3p cells in 
comparison to U87MG-luciferase/Mock cells (data not shown). Moreover, the 
anti-tumor growth effect of miR-3189-3p was also confirmed in nude mice 
bearing intracranial U87MG glioblastoma cells mock-transfected or 
transfected with miR-3189-3p mimic (Fig.15, C and D). Beginning at one 
week post-injection, the mean luminescence radiance for each tumor was 
collected. After two weeks we found that mice bearing U87MG/miR-3189-3p 
cells had a nearly 72% smaller tumors when compared to U87MG/Mock 
(Fig.15, C and D; p<0.0005).  
Since GDF15 and miR-3189 originate from the same transcript, we asked 
whether their expression would correlate with that measured in human brain 
tumor extracts. Frozen tissue samples from astrocytomas, glioblastomas and 
normal brains were utilized for total RNA isolation and were subjected to 
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quantitative RT-PCR. Results shown in Fig. 16A and B represent the 
relative expression (1/ΔCt) of the indicated RNA species normalized using 
RNU6B as reference gene. Interestingly, although GDF15 was not detected 
by real time PCR in normal brain tissues, its expression yielded a trend 
specific to tumor type with higher upregulation in glioblastoma than in 
astrocytomas (Fig. 16A; p<0.05). Conversely, miR-3189-3p levels were 
significantly lower in both astrocytomas and glioblastomas compared to 
control brain tissue (p<0.05 and p<0.001, respectively), and showed a trend 
that correlated with the tumor progression (Fig. 16B). Of the two major 
targets of miR-3189-3p, SF3B2 and p63RhoGEF, only SF3B2 showed a 
statistically significant increased in expression in both astrocytomas and 
glioblastomas compared to the control group (p<0.01 and p<0.05, 
respectively), Fig. 16C, while p63RhoGEF mRNA expression analysis did 
not result in significant changes between the three groups (Fig. 16D).  
 
GDF15 and miR-3189-3p expression upon fenofibrate stimulation is 
PPARα-independent 
 Next, we wanted to investigate the transcriptional factors that can be 
potentially involved in the fenofibrate-induced up-regulation of GDF15 and 
miR-3189-3p, with particular regard to PPARα, the receptor by which 
fenofibrate exerts its effects.   
As mentioned above, several studies have shown also PPARα-
independent activities of fenofibrate [152,154,159,169]. In detail, in a work of 
2009 Araki and colleagues, by analyzing microarray data of human 
endothelial cells treated with fenofibrate and with or without siRNA against 
PPARα, suggest that GDF15 is a PPARα-independent master regulator of 
fenofibrate action [159,169]. Here, we showed that both GDF15 and miR-
3189-3p up-regulation observed upon fenofibrate stimulation is PPARα-
independent as demonstrated by treating LN-229 with PPARα inhibitor (Fig. 
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17A) and by transfection assay with siRNA against PPARα (Fig. 17B). 
PPARα mRNA expression level was effectively downregulated by siRNA 
against PPARα but was not affected by scrambled siRNA. Results are 
expressed as fold change (2-ΔΔCt method) of the mRNA in siRNA scramble 
and siRNA PPARα transfected LN-229 cells compared to control 
(untransfected, MOCK). 
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Figure 8: Fenofibrate treatment up-regulates GDF15 mRNA and protein 
expression in LN-229 cells.  
A, Real-time PCR detecting GDF15 mRNA expression at the indicated time points 
after fenofibrate treatment. Results are expressed as fold change (2-ΔΔCt method) of 
the mRNA in fenofibrate-treated LN-229 cells compared to untreated. In the same 
experimental conditions, mature and precursor GDF15 proteins were detected by 
Western blots (B). Grb2 antibody was used to show equal loading of cellular lysates. 
C, ELISA to detect secreted mature (active) GDF15 protein in the culturing medium 
obtained from LN-229 cells treated with fenofibrate (FF) and control (no FF). The 
data represent change in GDF15 levels in medium from fenofibrate-treated cells 
compared to untreated. 
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Figure 9: MiR-3189-3p is upregulated and incorporated into the RNA-induced 
silencing complex (RISC) in cells treated with fenofibrate.  
A, Real-time PCR to detect miR-3189-3p and miR-3189-5p expression. Results are 
expressed as fold change of the microRNAs in fenofibrate-treated cells (FF) 
compared to untreated. B, Western Blot to detect Ago2 after immunoprecipitation of 
lysates obtained from untreated and fenofibrate-treated cells. Left over IP represents 
the fraction of lysates obtained after overnight incubation with Ago2 antibody or the 
control isotype IgG, and used as negative control. C and D, Real-time PCR detection 
of miR-3189-3p (C) and targets (D), SF3B2 and p63RhoGEF, incorporation into 
Ago2 following treatment with fenofibrate. The enrichment of microRNAs in RISC 
was calculated according to the formula 2 - (CtAgo2 – CtIgG) and normalized over RNU6B 
for microRNAs and GAPDH for mRNA. 
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Figure 10: Fenofibrate treatment results in down-regulation of miR-3189-3p 
target mRNAs and proteins in LN-229 cells.  
A, Real-time PCR data showing changes in p63RhoGEF and SF3B2 mRNAs after 
fenofibrate treatment for 24 and 48 hours. Results are expressed as fold change of 
the mRNA in fenofibrate-treated cells compared to the untreated (Untr). B, Real-time 
PCR showing expression of p63RhoGEF and SF3B2 mRNAs in mock-transfected 
(Ctrl), cells transfected with miR-3189-3p, and cells transfected with miR-3189-3p + 
anti-miR-3189-3p. Results are expressed as fold change compared to mock-treated 
cells. C, Western blots for SF3B2 and p63RhoGEF proteins performed on lysates 
from cells that were untreated or treated with fenofibrate (FF) for 48 hours. 14-3-3 
antibody was used to show equal loading of cellular lysates. D, Western blots for 
SF3B2 and p63RhoGEF proteins performed on lysates from cells transfected with 
mock, miR-3189-3p, or miR-3189-3p + anti-miR-3189-3p for 48 hours.  
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Figure 11: MiR-3189-3p directly targets the 3’UTR sequences of SF3B2 and 
p63RhoGEF. 
A, Luciferase assays of LN-229 cells co-transfected with psiCHECK2/SF3B2 3’UTR 
and the mutants in the miR-3189-3p putative binding sites (MS1 and MS2) and miR-
3189-3p +/- anti-miR-3189-3p (inhib). B, Luciferase assays of LN-229 cells co-
transfected with spiCHECK2/p63RhoGEF 3’UTR and mutants (MS1, MS2, MS3) 
and miR-3189-3p +/- anti-miR-3189-3p (inhib). Lucifarese and Renilla values were 
determined at 24 hours post-transfection. The data represent the ratio between 
Renilla Luciferase values and Firefly Lucifarese internal control for each group (n = 
2). MS1-3 indicate specific microRNA binding site mutants; DM and TM indicate 
double- and triple-binding site mutants.  
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Figure 12: MiR-3189-3p alters the morphology and impairs the growth and 
migration of LN-229 gioblastoma cells. 
A, Phase contrast images showing the morphology of LN-229 cells following 
trasnfection with miR-3189-3p or miR-3189-3p + anti-miR-3189-3p; original 
magnification 10X. Images were acquired at 48 hours post-transfection. B, Cell-
growth assay performed 72 hours post-transfection with mock (Ctrl), miR-3189-3p or 
miR-3189-3p + anti-miR-3189-3p and quatified using MTS reagent. Results are 
expressed as percent growth/mock-treated control. C, Cell cycle analysis of LN-229 
cells transfected with mock (Ctrl), miR-3189-3p and miR-3189-3p + anti-miR-3189-
3p. Cells were stained with Guava Cell Cycle reagent and cell cycle distribution (%) 
was quantified by flow cytometry using FACSAria. D,  Representative images of a 
scratch assay to monitor migration of controls (mock transfected) and miR-3189-3p 
transfected cells; original magnification 10X. Migration into the cell-free area was 
monitored by time-lapse imaging in a VivaView incubator.  
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Figure 13: MiR-3189-3p regulates LN-229 cell growth through the down-
regulation of SF3B2.  
A, Cell growth assay performed 72 hours after transient transfection of LN-
229/pcDNA3.1 (empty vector, EV) or LN-229/SF3B2 with miR-3189-3p. The inset 
shows levels of expression of SF3B2 in the stably transfected cells. Results are 
expressed as percent growth/mock-treated control. B, Cell growth assay performed 
48 hours after transient transfection of siSF3B2. C, Western blots for E2F-1 protein 
expression performed on lysates from cells transfected with mock, miR-3189-3p, or 
miR-3189-3p + anti-miR-3189-3p. 14-3-3 antibody was used to show equal loading 
of cellular lysates. 
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Figure 14: MiR-3189-3p regulates LN-229 cell migration through the down-
regulation of p63RhoGEF. 
A, Cell migration assay performed 48h after transient transfection of sip63RhoGEF. 
B, Diagram showing the results of a scratch assay to monitor migration of cells 
stably expressing the p63RhoGEF gene (GEF). Migration into cell-free area was 
monitored by time-lapse imaging in a VivaView incubator. The inset shows levels of 
expression of p63RhoGEF protein in two clones of the stably transfected LN-229 
cells and control empty vector (EV).  
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Figure 15: Expression of miR-3189-3p results in growth inhibition of human 
glioblastoma cells in mice. 
A, Fluorescent images of pmCherry/LN-229 cells mock-transfected (Control) or 
transfected with miR-3189-3p implanted subcutaneously in nude mice (p<0.05). B, 
Plot of tumor burden 3 weeks post-injection with control or miR-3189-3p-transfected 
LN-229-mCherry cells. Tumor burden was quantified by acquiring fluorescent 
emission at 610 nm wavelength. Relative fluorescence values are represented as 
photon flux per second, square centimeter and surface radiance (p/sec/cm2/sr). C, 
Luminescent images of U87MG-luciferase cells mock-transfected (Control) or 
transfected with miR-3189-3p implanted intracranially in nude mice (p<0.0005). D, 
Plot of tumor burden 2 weeks post-injection with control or miR-3189-3p-transfected 
U87MG-luciferase cells. Tumor burden was quantified by acquiring luminescence 
emission. Relative luminescence values are represented as photon flux per second, 
square centimeter and surface radiance (p/sec/cm2/sr). 
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Figure 16: Expression of miR-3189-3p inversely correlates with tumor grade 
and SF3B2 and p63RhoGEF expression in human clinical samples.   
A, Relative expression of GDF15 mRNA in human astrocytoma and glioblastoma 
clinical samples, calculated as 1/ΔCt. Note that GDF15 mRNA was undetectable in 
control brain samples. B – D, Relative expression of miR-3189-3p, SF3B2, and 
p63RhoGEF mRNA in normal control (Ctrl), astrocytoma, or glioblastoma clinical 
samples. Results are expressed as 1/ΔCt values. T-test results (p-values) are shown 
in the graphs.  
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Figure 17: Expression of GDF15 and miR-3189-3p upon fenofibrate stimulation 
is PPARα-independent.  
A, Real-time PCR detecting GDF15 mRNA, PPARα mRNA and miR-3189-3p 
expression in fenofibrate-treated LN-229 at 48 hours time-point with or without 
PPARα-inhibitor (GW 9962). Results are expressed as fold change (2-ΔΔCt method) 
of the mRNA or of the microRNA in fenofibrate-treated LN-229 +/- GW 9962 
compared to untreated (Ctrl). B, Real-time PCR detecting GDF15 mRNA, PPARα 
mRNA and miR-3189-3p expression at 48 hours time-point after transfection. LN-
229 cells were incubated with 100 nM of siRNA against human PPARα or 100 nM 
scrambled siRNA.  
 
 
 
 
82 
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 
83 
	  
GDF15 is a secreted protein that plays a central role in diverse 
biological processes including differentiation, proliferation, apoptosis, and 
regulation of the inflammatory response [123]. In cancer, there are 
contradictory reports on the tumor promoting and tumor suppressive 
properties of GDF15. For instance, increased expression of GDF15 has 
been observed during the progression of several aggressive cancers, such 
as melanoma, colorectal, prostate, pancreatic, breast and brain. Conversely, 
cytotoxic agents such as etoposide and doxorubicin have been shown to 
increase GDF15 expression [123]    
MiR-3189 has been previously predicted to be a mirtron expressed in 
melanoma [185] but no experimental evidence has been demonstrated so 
far. An inhibitory effect of miR-3189-5p on TGFβR2 has been hypothesized 
[186], but a function for neither miR-3189-3p nor miR-3189-5p has been 
identified. Mirtrons are microRNAs encoded within introns and their 
biogenesis follows a non-canonical, Drosha/DGCR8-independent, pathway 
that relies on the mRNA splicing and on RNA lariats debranching enzymes 
[31]. Differently from canonical pre-miRNA stem-loops, microRNAs 
generated from the 3’ ( -3p) of the mirtron hairpin appear to be more stable 
than those generated from the 5’ ( -5p) [187]. This may explain why, even if 
miR-3189-5p expression was slightly and variably induced by mitogenic 
stimuli (10% FBS), the microRNA was not detected in the Ago2-
immunoprecipitated complex (data not shown).  
MiR-3189-3p together with two of its major predicted targets, SF3B2 
and p63RhoGEF, co-immunoprecipitated with Ago2 (Fig. 9), suggesting a 
functional role for this microRNA. A direct inhibitory effect of miR-3189-3p on 
the 3’ UTR sequence of SF3B2 and p63RhoGEF was further demonstrated 
by luciferase assay (Fig. 11). Fenofibrate treatment and over-expression of 
miR_3189-3p in LN-229 cells also resulted in down-regulation of SF3B2 and 
p63RhoGEF (Fig. 10). However the presence of antago-miR against miR-
3189-3p in fenofibrate-treated cells did not rescue SF3B2 or p63RhoGEF 
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expression or protect cells from apoptosis (data not shown). Given the broad 
range of effects triggered by fenofibrate [152,156,166] it is possible that 
changes in microRNA expression may only partially contribute to its 
biological function. Nevertheless, expression of miR-3189-3p had a strong 
biological effect on LN-229, impairing their migration and growth. These 
effects were shown being mediated through downregulation of p63RhoGEF 
and SF3B2, respectively (Fig. 13 and 14). With respect to p63RhoGEF 
previous reports have also shown a role for this protein in cell migration. 
Specifically, Hayashi et al. demonstrated that the expression of p63RhoGEF 
is essential for lamellipodial polarization during serum-induced chemotaxis 
[183]. Our findings are in agreement with a role for p63RhoGEF in cell 
motility, since siRNA against p63RhoGEF impaired migration of LN-229 cells 
(Fig. 14A). Our results showing the inhibitory effect of miR-3189-3p on 
p63RhoGEF overexpressing cells (Fig. 14B), demonstrate that inhibition of 
cell migration by miR-3189-3p is only partially due to the downregulation of 
p63RhoGEF. Such result may not be surprising, since other members of the 
RhoA family of guanine nucleotide exchange factors, as SLIT-ROBO Rho 
GTPase activating protein 2 (SRGAP2) and Rho guanine nucleotide 
exchange factor (GEF) 12 (ARHGEF12) are other putative targets of miR-
3189-3p. Likewise, the striking change in cellular morphology upon 
expression of miR-3189-3p might be the result of this microRNA targeting 
multiple genes involved in cytoskeletal remodeling.  
It has been reported that the expression of the transcription factor 
E2F-1 is dependent on the presence of SF3B2 in the cell [177]. Furthermore, 
E2F-1 has been shown to be a master regulator of cell cycle progression 
[188,189]. Therefore, it is not surprising that SF3B2 downregulation by miR-
3189-3p in glioblastoma delayed cell growth. In our studies, this effect was 
shown to be dependent on SF3B2, as overexpression of this gene in the 
presence of miR-3189-3p restored the proliferative capacity of LN-229 cells. 
The antiproliferative activity of miR-3189-3p was also demonstrated in vivo 
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both in nude mice bearing subcutaneous LN-229 tumors (Fig. 15A and 15B) 
and in nude mice bearing subcutaneous U87MG tumors. Finally, results 
obtained from nude mice bearing intracranial U87MG tumors confirmed the 
antiproliferative activity of miR-3189-3p (Fig. 15B and 15D). 
Importantly, miR-3189-3p and its targets SF3B2 and p63RhoGEF, 
along with GDF15 were differentially expressed in clinical samples of glial 
tumors. GDF15 mRNA was not detected in normal brain tissue, but its 
transcripts were significantly increased in glioblastomas compared to 
astrocytomas (Fig. 16A). Expression levels of miR-3189-3p and its target 
SF3B2 were inversely correlated, as the microRNA was downregulated and 
SF3B2 mRNA was upregulated in astrocytomas and glioblstomas when 
compared to normal tissue (Fig. 16, panels B and C). Although expression 
of p63RhoGEF mRNA may indicate a trend in increased levels in both glial 
tumors when compared to controls, the difference was not statistically 
significant (Fig. 16D). Overexpression of GDF15 protein or treatment of LN-
229 cells with its soluble version did not elicit any morphological or biological 
effects in LN-229 cells in vitro (data not shown). Similarly, the anti-miR-3189-
3p did not protect fenofibrate-treated cells from apoptosis, indicating that 
upregulation of miR-3189-3p is not required for fenofibrate-mediated cell 
death. Nevertheless, our study shows that expression of GDF15 and its co-
encoded miR-3189-3p is regulated in brain tumors, and that miR-3189-3p 
acts as a tumor suppressor.  
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In this study, we have analyzed the role of GDF15 and its co-
encoded miR-3189 in glioblastoma. In particular we focused on the 
characterization of the function of miR-3189-3p, which we found to be 
interestingly upregulated together with GDF15 after fenofibrate treatment in 
LN-229 cells. Numerous published works demonstrate the anticancer 
properties of fenofibrate, while contradictory evidences exist about the 
tumor-promoting or the tumor-suppressive role of GDF15. Moreover, the 
functions for neither miR-3189-3p nor miR-3189-5p have been identified so 
far. Thus this is the first report where the role of these two microRNAs, and 
in particular miR-3189-3p, has been investigated in order to study their 
possible participation in the biological function of GDF15. 
Results presented herein indicate that miR-3189-3p has a tumor-
suppressor function by acting on two of its major predicted targets, SF3B2 
and p63RhoGEF, involved respectively in cell-proliferation and cell-
migration. Indeed transfection of LN-229 cells with miR-3189-3p resulted in a 
delayed cell-growth and in a slowdown of migration. The validation of the 
targeting on these two genes was conducted by performing both Luciferase 
assays and Ago2 immunoprecipitation. Luciferase assays demonstrated the 
downregulation of SF3B2 and p63RhoGEF through the binding of miR-3189-
3p to their 3’UTR. Ago-2 immunoprecipitation experiments upon fenofibrate 
stimulation showed an enrichment of miR-3189-3p together with SF3B2 and 
p63RhoGEF in Ago-2 complexes, suggesting that miR-3189-3p was 
functionally associated with Ago-2. In addition, both the subcutaneous and 
the intracranial injection in mice of cell-lines bearing the miR-3189-3p 
resulted in inhibition of tumor growth, strongly validating the antiproliferative 
activity of this microRNA. Importantly, the tumor-suppressor activity of miR-
3189-3p has been confirmed by conducting the major experiments in other 
glioblastoma cell-lines (U87MG, T98G), corroborating the potential clinical 
implication of our findings.  
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Analyses on clinical specimens of brain tumors revealed that miR-
3189-3p is under-expressed in astrocytoma and glioblastoma samples, 
showing an opposite trend compared to its targets, which is in agreement 
with the results obtained in vitro validating its role as a tumor-suppressor. 
Moreover, the opposite trend observed in clinical samples between GDF15 
and miR-3189-3p may explain its effect in the biological function of GDF15 
that is its contribution to determine the oncogenic role of the protein in the 
late stages of the tumor progression. 
Altogether, our studies have demonstrated that miR-3189-3p 
controls the growth and migration of glioblastoma cells by targeting the 
SF3B2 and p63RhoGEF mRNAs. Importantly, drugs, such as fenofibrate, 
that increase miR-3189-3p expression have the potential of slowing down 
glioblastoma growth and central nervous system (CNS) invasion. For 
instance we have found that stimulating LN-229 with other treatments 
besides fenofibrate, such as Carnosic Acid and N-acetylsalicylic Acid (data 
not shown), are able to induce an up-regulation of both GDF15 mRNA and 
miR-3189-3p expression.  
Further studies on the biological activity of this microRNA using glioblastoma 
as a model may help the development of new supplemental anti-cancer 
therapy supporting both the existing and emerging anti-glioblastoma 
treatments. 
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